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 Combination therapy is preferred over monotherapy to treat cancer as it can show 
better therapeutic outcomes and also delay the onset of resistance by targeting multiple 
cell-survival pathways in cancer cells. Rationally developed combinations with monoclonal 
antibodies and small molecule drugs in the form of antibody-drug conjugates or antibody 
nanoparticle conjugates allow us to take advantage of the cellular targeting of the potent 
cytotoxic agents, thereby widening the scope for dose reduction while maintaining the 
required therapeutic response. This can in turn improve patient tolerability by reducing the 
off target toxicities. For the therapy of ErbB2 positive breast cancer, the monoclonal 
antibody, Trastuzumab, is the FDA approved therapy. The receptor tyrosine kinase, ErbB2 
is a viable target in 20-25 % breast cancer patients due to its overexpression. Its 
degradation is associated with slower progression of the disease and increased survival 
times. While the monoclonal antibody Trastuzumab (Herceptin™) is the first line therapy 
in such patients, monotherapy with Trastuzumab has shown little benefit and therefore 
must be given with chemotherapeutic agents. Such combinations also help in delaying the 
development of resistance to Trastuzumab, since multiple cellular pathways can be 
targeted simultaneously. ErbB2 is a client protein of heat shock protein 90 and 17-N-
allylamino-17-demethoxygeldanamycin (17-AAG) is a potent inhibitor of HSP90. Previous 
work in our lab has demonstrated strong synergy of action between 17-AAG and a model 
cytotoxic agent doxorubicin. In order to further improve the efficacy of the therapy, our 
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goal was to replace doxorubicin with a more potent, clinically relevant agent paclitaxel 
(PTX), which has been shown to have strong synergistic antitumor effect with 17-AAG in 
ErbB2-driven breast cancers. Since synergy of such therapy is often sequence and dose 
ratio specific, co-delivery of the drugs via the same vehicle is desirable as well as 
beneficial. For this purpose, polymeric micelles prepared from a biodegradable block 
copolymer were chose.  Polypeptides have an inherent property to assemble into 
supramolecular structures in solution. The formation of supramolecular structures is a 
controlled and organized process that depends by and large on the nature of the 
polypeptide and conditions of the solvent it is exposed to. Formation of amphiphilic 
copolymers based on such polypeptides can allow for tailoring the assembly process to a 
predefined nanoscale supramolecular structure, which can then be used as drug delivery 
vehicles. The overall process of self-assembly of such amphiphilic copolymers can then 
be regarded as a complex phenomenon of structural organization that is governed by the 
nature of constituent hydrophilic and hydrophobic blocks, their relative lengths, as well as 
properties of the solvent-phobic block that is the driving force for self-assembly. The 
inherent biocompatibility and biodegradability of polypeptides is of additional advantage 
for their biological applications. For the purpose of the current study, amphiphilic block 
copolymer with following composition was chosen: polyethylene glycol (PEG) as the 
hydrophilic, stealth imparting block and polyleucine (PLeu) as the hydrophobic part and 
the initiator of micelle formation in aqueous environment. The variables explored in the 
current study were altering the ratio of lengths of constituent blocks as well as chirality of 
PLeu block and the temperature of solvent used for preparation of micelles via the film 
rehydration method. The impact of all these variables on the thermodynamic stability as 
well as type of secondary structures formed and the influence of these attributes on the 
ability of the micelles to encapsulate a combination of hydrophobic drugs into their core 
are also described. Dual drug-loaded micelles thus prepared could load 17-AAG and PTX 
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in a ratio 2:1 by weight. The formulation showed a high level of synergy on BT-474 cells 
that express a high amount of ErbB2 while the synergy was negligible in ErbB2low MCF-
7 cells. The strong synergy also observed when the formulation was tested in an orthotopic 
breast cancer mouse model developed using ErbB2 overexpressing BT-474 cells, and an 
arrest in the growth of tumors in animals treated with dual drug-loaded micelles was 
observed, while both 17-AAG and PTX were used at sub therapeutic doses of 10 mg and 
5 mg equivalents per kg body weight. The lower doses also helped avoid toxicity 
associated with the therapy. We also show the importance of simultaneously delivering 
the two drugs via a single carrier system as opposed to cocktail of individual drug-loaded 
micelles administered at equivalent doses, which has a better therapeutic outcome than 
the cocktail therapy. These combination drug-loaded micelles were developed as a 
platform for chemotherapy with Trast. The triple therapeutic system of Trast with 
combination drug-loaded micelles containing 17-AAG and PTX exhibited an even stronger 
anticancer effect, with complete regression of tumors at the end of treatment, which 
reached a palpable size again after day 45 with much slower progression than other 
treatment controls. 
Pancreatic cancer (PC) is one of the most lethal malignancies, due to aggressive 
tumorigenicity, early metastasis and development of drug resistance to standard care 
chemotherapy. Since its approval in 1997, Gemcitabine (Gem) has been the first-line 
treatment for advanced disease. However, there is no standard second-line therapy after 
Gem failure. FOLFIRINOX, a combination of four agents, folinic acid, fluorouracil, 
irinotecan and oxaliplatin was approved by the FDA in 2010. The rationale for this 
combination was based on these drugs having a different mechanism of action, and, more 
importantly, non-overlapping toxicities. In cases that could tolerate FOLFIRINOX, an 
overall improvement in the survival times as well as quality of life was noted. However, 
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even the toxicities are non-overlapping, the cumulative toxicity profile for FOLFIRINOX 
can become the dose limiting factor. In the first trial itself, 50.8% of the patients needed 
dose adjustment. The common toxicities observed with FOLFIRINOX include Febrile 
neutropenia, Thrombocytopenic bleeding, ≥ grade 3 platelets, Grade 2 persistent 
neurotoxicity, Grade 3 persistent neurotoxicity  OR Grade 4 neurotoxicity and many more 
non-hematological toxicities. Most of the toxicities are severe enough to require 
discontinuation of the treatment or switching to lower doses or alternative agents. The 
combination of Gem with Cisplatin (CDDP) has been explored in clinical trials for 
metastatic disease. As a part of FOLFIRINOX, platinum compounds showed significant 
efficacy. Cisplatin acts by damaging the DNA. It is known to first get converted into the 
aqua form within the cell, which happens by the replacement of the labile chloro groups 
with water molecules. This active form is then able to form covalently linked adducts with 
the DNA. This initial assault then goes on to activate a series of signaling pathways that 
ultimately lead to apoptosis and cell death. The DNA adducts thus formed can cause 
distortion of the DNA and subsequent recognition by various cellular proteins. This leads 
to problems in DNA synthesis and replication and is reported to cause a prolonged G2 
cell-cycle phase arrest. However, the exact mechanism of activation of the apoptotic 
pathways remains unclear. On the other hand, gemcitabine is a deoxycytidine analog. Its 
mechanism of activation involves conversion into its triphosphate form, which can then be 
incorporated into the DNA as a false nucleotide. Usually, one more deoxynucleotide can 
be incorporated into the DNA before the synthesis stops. Another minor mechanism of 
action of gemcitabine is its ability to inhibit ribonucleotide reductase, which plays a key 
role in the repair mechanism of the DNA. Many studies report the benefit of administration 
of gemcitabine prior to that of cisplatin; the reason cited for this is the increase in the 
formation of Pt-DNA adducts when the DNA had already been damaged and exposed due 
to the incorporation of deoxycytidine or active gemcitabine. The gemcitabine in turn 
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inhibits the repair of the formed Pt-DNA adducts as well as reduces the efficacy of 
nucleotide excision repair by its ability to inhibit the action of ribonucleotide reductase. On 
the other hand, when Pt compounds are administered prior to gemcitabine, the formed Pt-
DNA adducts can no longer allow for the incorporation of gemcitabine and that leaves no 
scope for gemcitabine to act. Our preliminary in vitro studies with the free drugs on T3M4 
Simple Cells (COSMC deleted cells) showed that synergy of the combination is schedule-
dependent, and Gem administration followed by CDDP showed the most potent cytotoxic 
activity. However, this combination proved to be only marginally effective in actual practice 
due to combined increased toxicity of both the agents. We have shown that encapsulation 
of CDDP in polymeric nanogels with cross-linked ionic cores enhanced its tumor 
accumulation and improved its safety profile. Additionally, sustained release profile of 
CDDP from nanogels allows for the administration of free Gem and CDDP loaded 
nanogels in a single injection while still retaining schedule-dependent synergy of the 
combination. Pancreatic ductal adenocarcinoma cells are known to express truncated O-
glycans (Tn and STn antigens) and it was shown that decorating the nanogels with an 
antibody directed against this antigen further enhanced their uptake by tumor cells while 
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1.1 Therapeutic approaches in cancer 
The National Cancer Institute defines cancer as a group of diseases arising due to defects 
in the genes responsible for the control of cell division. It can be inherited or caused due 
to environmental factors or exposure to known carcinogens. Latest statistics indicate that 
nearly 40 percent of men and women would be diagnosed with cancer during their lifetime 
and the rates of mortality resulting from cancer is on the rise. It is a disease with 
heterogeneity that makes it difficult to have a standard therapy that can be equally 
effective even within the same type of cancer. The complexity of the disease arises from 
the fact that each individual’s cancer can have a unique combination of genetic changes, 
which continue to diversify as the cancer progresses. This makes it very difficult to combat 
the disease with a single therapeutic approach. Hence, a variety of combination 
approaches are adopted, which are summarized in fig. 1.1. Briefly, they consist of 1) 
Surgery: this is the most preferred option where feasible; most of the tumor mass is 
removed surgically, and is followed by adjuvant therapies like radiation or chemotherapy 
to eradicate the remaining cells in the tissue. However, surgery is not an option for very 
deep-seated tumors at sites that are inaccessible or if there is extensive metastasis. 2) 
Immunotherapy: it involves taking help of the immune system directly or indirectly to fight 
cancer. Some of the approaches in immunotherapy include use of monoclonal antibodies 
that specifically mark cancer cells for clearance by the immune system, adoptive transfer 
of T cells to boost the body’s natural immunity, cytokines like interferons and interleukins 





stages of the disease; before surgery, it can be used to shrink the tumor for ease of 
removal,  intraoperatively, for better access to the tumor site and avoid exposure to healthy 
areas or after the surgery, to kill the residual cancer cells. 4) Chemotherapy: it is the most 
popular form of therapy and can be given post-surgery or even as a stand-alone treatment 
option. There are multiple chemotherapeutic agents with different mechanisms of action 
that can be employed for the purpose. Like radiation, it can either be used prior to surgery 
to reduce the tumor volume or post-surgery to kill the residual cancer cells.  Chemotherapy 
can involve the use of either single or multiple agents depending on the severity of the 
disease as well as its response to treatment. Overall, the type of therapeutic approach 
adopted to combat cancer depends on subtype of the disease as well as its sensitivity to 
the approach adopted as well as its feasibility. Often, the side effects can also be a limiting 
factor for the use of a specific approach and can depend on individual susceptibilities.  
Figure 1. Therapeutic approaches for cancer treatment 
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1.2 Chemotherapy – the need for combination therapy 
1.2.1 Chemotherapy  
Therapeutic approaches in cancer have traditionally involved the use of cytotoxic agents 
and the majority of them act via induction of apoptosis in the cancer cells. This apoptosis 
is induced via damage to a key cell organelle like the DNA or by hampering the cell division 
process like microtubule inhibition or by affecting the synthesis of key proteins for normal 
cellular function. These approaches are summarized in Fig. 2. 1. Apoptotic signals are 
generated within the cells when chemotherapeutic agent causes an injury that can make 
the cell dysfunctional. This process can be divided into 3 phases. Phase I is where the 
injury first occurs. The site of injury depends on the type of drug used and maybe either 
the DNA, RNA or microtubules. The cell realizes the extent of damage caused by the initial 
assault in Phase II, by mechanisms that are yet to be discovered. For example, treatment 
of some T-cell leukemia lines with doxorubicin results in upregulation of the ligand to the 
Fas receptor, which may mediate the ability of doxorubicin to kill these cells 2. This 
response depends on the sensitivity of the cell to the injury and lack of defense or 
corrective mechanisms decide the extent of sensitivity. Phase III is the final phase where 
apoptotic signaling is initiated. For example, γ-radiation causes the induction of the pro-
apoptotic Bax in radiosensitive but not in radio-resistant cells. This may drive cells to 
apoptosis 3. In this phase, the cells undergo the orderly breakdown of macromolecules 
through the operation of proteases, endonucleases, transglutaminases, and possibly 
lipases. Other cell types may preferentially execute programs of cell cycle arrest and 
damage repair in response to these same signals. Although such a decision point appears 
critical in imparting selectivity of responses to similar stimuli, little is known concerning its 


























































































damage to be irreversible, it undergoes apoptosis and subsequent death. Thus, the above 
listed process can be described as a general mechanism of action for single drugs that is 
monotherapy in cancer.  
1.2.2 Development of resistance  
The development of resistance to monotherapy is a very common phenomenon that is 
quick to occur, while many cells are inherently resistant to apoptosis. These cancers may 
very well have disarmed regulatory mechanisms that survey damage or injury. This is 
supported by the frequent mutations in p53, which appears to play a critical role in the 
response to DNA damage. Other mutations may exist that also allow these cancer cells 
to escape suicide. If chemotherapeutic agents act primarily to induce apoptosis, then it 
becomes obvious that these cancer cells may be a priori resistant to cell death in response 
to these agents. If this is the case, then the hematologic and germ cell malignancies may 
be the exceptional malignancies. For some reason these cancers may have traded the 
increased susceptibility to apoptosis for some survival or growth advantage. What the era 
of cytotoxic chemotherapy may have accomplished is to segregate cancers into two 
groups: those that are prone to apoptosis and those that are resistant 1.  Various 
mechanisms have been proposed to explain the mechanism of resistance development 4. 
Altered Membrane Transport is probably one of the most significant forms of resistance 
against the variety of currently used antineoplastic agents. It is by the action of a group of 
membrane proteins which extrude cytotoxic molecules, keeping intracellular drug 
concentration below a cell-killing threshold. These ATP-dependent multidrug transporters 
belong to the ubiquitous superfamily of ATP-binding cassette (ABC) proteins. The ABC 
proteins have been grouped into 7 subclasses ranging from ABCA to ABCG 5-7 based 
upon genomic organization, order of domains and sequence homology. The MDR1 gene, 
which encodes P-glycoprotein (P-gp; MDR1, ABCB1) 8-11, a phosphorylated and 
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glycosylated 170-kDa protein of 1,280 amino acids, is the most widely observed 
mechanism in clinical transport-associated MDR 11-14. Genetic responses may also decide 
the fate of therapy. Cells can compensate for the action of inhibitors by overexpressing 
the target protein; the administered concentration of the drug would then be insufficient to 
show desired inhibitory effects.  P-gp activity is also related to the status and level of 
activity of the MDR1 gene. Rifampicin can induce MDR1 expression. Induction of intestinal 
P-gp by rifampicin has been shown to be the major mechanism responsible for reduced 
digoxin levels during concomitant rifampicin therapy; in healthy male volunteers, the oral 
bio-availability of digoxin decreased by 30% and intestinal P-gp levels were induced 3.5-
fold during rifampicin therapy 15,16. Many drugs act by damaging the DNA or by inhibition 
of the enzymes responsible for DNA repair. To compensate, cells can enhance the activity 
of repair enzymes. Excision repair cross-complementing protein (ERCC1), most likely a 
DNA-binding protein, is another example of a DNA repair protein that may be involved in 
recognition of cisplatin damage; its expression is elevated in cisplatin- and carboplatin-
resistant cells compared with that in cells sensitive to cisplatin 17,18. The target molecules 
in the cells can undergo alterations in such a manner that their binding affinity to the drug 
molecules is reduced to the extent that the drugs are no longer effective. A classic example 
of this phenomenon is anti-estrogen therapy in breast cancer by agents like tamoxifen. 
The cells lose estrogen receptors overtime and the initially responsive cancer then 
becomes non-responsive, although a temporary response to other estrogen receptors like 
aromatase inhibitors might be seen temporarily 19,20. Target molecules may also disappear 
from cancer cells as a result of the loss of the corresponding gene. Chromosomal losses 
are a common feature of cancer. Duesberg et al. 21,22 have suggested that it is the 
aneuploid nature of cancer cells that best explains the development of MDR.  Another 
physiological response to the presence of drugs is the overexpression of drug-
metabolizing enzymes or carrier molecules; e.g. the increased production of glutathione 
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23 or ubiquitin contributes to inactivation of the drug by forming conjugates that are 
excreted. Resistance to cisplatin in ovarian carcinoma cells is associated with increased 
expression of dihydrodiol dehydrogenase 24. Serum levels of interleukin (IL)-6 have been 
found to be elevated in patients with various types of cancer. Conze et al. 25 demonstrated 
that autocrine production of IL-6 by breast cancer cells could promote resistance to 
chemotherapy. Cells sensitive to chemotherapy did not express appreciable IL-6, whereas 
high levels were detectable in multidrug-resistant cells. Studies on breast cancer cells 
have also suggested involvement of the extracellular matrix in drug resistance 26. It is 
known that out of different pathways, apoptosis can also be mediated by activation of the 
Fas/Fas-L pathway, which is the extrinsic pathway of induction of apoptosis. These 
authors showed that ligation of b1 integrins by their extracellular matrix ligands inhibits 
apoptosis mediated by paclitaxel and vincristine, which activate this pathway. These 
agents act by causing release of mitochondrial cytochrome c. Integrin mediated protection 
from the drug-induced apoptosis and inhibition of cytochrome c release were dependent 
on the activation of the PI3 kinase/Akt pathway. Song et al. 27 have shown that chemo 
resistance may be induced by extracellular factors in tumor-bearing organs. Comparing 
chemo sensitivity and proteins in different tumors and different culture systems, they found 
elevated levels of acidic and basic fibroblast growth factors in the media of solid and 
metastatic tumors. These conditioned media induced broad-spectrum resistance to drugs 
(paclitaxel, doxorubicin and 5-FU) with diverse structures and mechanisms of action. 
Application in combination, of these two growth factors, could produce a 10-fold increase 
in drug resistance, whereas suramin, a known inhibitor of fibroblast growth factors, was 
able to reverse this resistance. Thus, with monotherapy, cells can in general adopt several 
mechanisms to develop resistance. 
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1.2.3 Approaches to overcome resistance - combination therapy         
As discussed above, cancer cells can develop multiple pathways of overcoming the toxic 
effects of a single anticancer drug. The most logical way to overcome resistance therefore 
is the use of a combination of drugs that can target multiple, distinct pathways so that the 
cells cannot find a mechanism to cope with the damage. The general guidelines for 
choosing drugs in combination therapy are: 1) drugs that target different pathways 
synergistically so as to achieve maximum benefit and explore the possibility of reducing 
the dose of individual agents 28,29; 2) the drugs do not have overlapping toxicities and the 
combination is not antagonistic; 3) a combination that can be administered since early 
onset of the disease where the drugs have similar administration cycles so that there is 
minimum gap between treatments for recovery of sensitive healthy tissue 4,28-30. The many 
advantages of combination therapy are summarized in Fig 1.3. 31. Many approaches may 
be used to assess the extent of synergy that drug combinations have, the Chou and 
Talalay analysis being the most popular amongst them 32. Synergy essentially allows us 
to see better response than sum of effects of individual drugs. This effect may be seen 
irrespective of whether the drugs act on the same pathway or different ones 32. Chiang et 
al. have shown that an mTOR inhibitor, RAD001 has strong synergy with gem or PTX in 
a heterogeneous group of non-Hodgkin lymphoma cell lines. Their observations indicated 
that mTOR inhibition sensitized the cells to apoptosis induced by gemcitabine or PTX, and 
this ultimately activated caspase-dependent apoptosis to a greater extent than 
monotherapy with PTX or gem 33. As described earlier, one of the main reasons for the 
development of resistance is the presence of efflux pumps and P-gp, multidrug resistance 
protein 1 (MRP1) and breast cancer resistance protein (BCRP) are some of the most 
overexpressed efflux pumps in human cancers 34. 
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Figure 3. Advantages of combination therapy over monotherapy. Adapted from 31.   
Thus, it is logical to co-administer P-gp inhibitors with cytotoxic agents to prevent or 
reverse MDR 35. Recently, Hubensack et al. showed a significant elevated concentration 
of paclitaxel in the brain domain of nude mice when administrated with elacridar and 
tariquidar (both are third-generation P-gp inhibitors), caused by downregulation of P-gp 
expressed at the blood–brain barrier 36. In another Phase I clinical trial, zosuquidar was 
co-delivered with daunorubicin and cytarabine to older acute myeloid leukemia patients 
and the results demonstrated increased anticancer activity experienced by patients 
overcoming drug resistance 37. Since synergistic effects are much greater than the additive 
effect of individual components, it is possible to keep the disease in check with much lower 
doses of individual drugs. This helps spare healthy tissues from chemotherapy-related 
toxicities and increases patient tolerance. It was shown that one such combination of 
carboplatin and gem in a small group pf patients with metastatic ovarian cancer 
administered at sub therapeutic doses resulted in significant antitumor activity without any 
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signs of hematological toxicity 38. In another study, Bava et al. co-administered the herbal 
drug curcumin with the cytotoxic anticancer drug paclitaxel with a view to reducing the 
dose-limiting toxicity exerted by paclitaxel on systemic delivery, and they demonstrated 
that combination therapy not only reduced the dose of paclitaxel but also demonstrated 
increased anticancer cytotoxic activity compared with paclitaxel alone in HeLa cells 39. In 
conclusion, synergistic combinations can increase patient compliance for treatment as 
they have the potential to reduce toxic effects, lower frequency of administration and delay 
the onset of MDR 32,40,41.    
1.2.3.1 Types of combination therapies in clinical practice 
Combination therapy is a broad term that covers the application of more than one 
technique or agent that can be injurious to cancer cells. The most common approaches 
involve combination of various cytotoxic drugs, inhibitors of oncogenic pathways, 
chemotherapeutic drugs with radiotherapy or hormone therapy or immunotherapy. These 
approaches are summarized in fig 1.4. For hormone dependent breast cancer, different 
methods are adopted to reduce or stop the effect of estrogen on cancer cells. Aromatase 
is an enzyme responsible for the production of estrogens. Therefore, inhibitors of 
aromatase can stop the production of estrogen and have been used intensely for the 
treatment of breast cancer. Similarly, the use of various hormone receptor inhibitors (such 
as tamoxifen and raloxifene) can block the overexpressed cancer cell receptor and 
prevent its activation for consequent uncontrolled proliferation. Recent studies have 
suggested that endocrine therapy can be used with adjuvant bisphosphonate therapy 
(using zoledronic acid) for the treatment of breast cancer. Zoledronic acid prevents 
aromatase-inhibitor-associated bone loss in post-menopausal women with breast cancer 
and it represented a cost-effective treatment for the prevention of bone loss and/or 
fracture 42. Combination of chemotherapy and radiotherapy is one of the most promising 
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strategies for current cancer therapeutics. It has been shown to improve patient survival 
and the locoregional control of various cancers when compared with radiotherapy alone 43. 
In the early 1970s, the combination of 5-fluorouracil (5-FU) and mitomycin C with 
radiotherapy demonstrated improved results for patients with locally advanced stages of 
anal cancer 44. A randomized Phase II clinical trial was performed to examine the 
combination of radiotherapy and a prostate-specific-antigen-based vaccine in prostate 
cancer patients and the results have shown that radiotherapy makes the tumor more 
susceptible to vaccines 45. Different monoclonal antibodies can also be used to block 
oncogenic signaling. Antibodies can also be used to activate the immune system to kill the 
cancer cells through the activation of complement system or by direct cytotoxic effect 
which is termed as antibody-dependent cellular cytotoxicity (ADCC) 46. Studies conducted 
by Tanabe et al. have demonstrated that the combinations of mitomycin C and 
methotrexate showed significant antitumor activity in metastatic breast cancer patients 
pretreated with anthracycline and taxanes 47. In another study, Arkenau et al. showed that, 
after curative resection of stage III colon cancer, adjuvant treatment with 5-FU plus 
leucovorin is generally well tolerated and the long-term follow-up study demonstrated that 
this combination administered for 12 cycles significantly reduced tumor relapse and 
improved survival 48. The other combinations of drugs in cancer therapeutics include a 
combination of paclitaxel with carboplatin or with vinorelbine for the treatment of nonsmall-
cell lung cancer 49. Among different combination therapies the most practiced and well 
researched therapy method is co-treatment with multiple chemotherapeutic drugs. 
Therefore, current trends in anticancer research have progressively concentrated on the 
development of new combinations of anticancer drugs with a view to overcoming the 
limitations frequently associated with conventional chemotherapy 31. 
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Figure 4. Different approaches of combination therapy for the treatment of cancer. 
Adapted from 31. 
1.2.3.2. Combination therapy in breast cancer 
Breast cancer is one of the most commonly encountered gynecological malignancies in 
women and claims many lives worldwide. About 1 in 8 U.S. women (12%) is prone to 
develop breast cancer during her lifetime. Latest cancer statistics indicate that in 2016, an 
estimated 246,660 new cases of invasive breast cancer are expected to be diagnosed in 
women in the U.S. (Source: Breastcancer.org). Despite excellent advances in medical 
diagnostics and early detection, it has been observed that up to five percent of the patients 
diagnosed with breast cancer already have metastatic disease at the time of diagnosis, 
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while around thirty percent of the cases with primary tumor are expected to progress to 
metastatic disease (EarlyBCTCG). While medical advances have improved the overall 
survival of patients with breast cancer, the disease itself is known to be very 
heterogeneous and has profound complexity at the genetic level, which makes it a great 
challenge to find a treatment solution that can be effective in the vast majority of the cases 
50. Overexpression or aberrant activity of many growth factor receptors is associated with 
oncogenic signaling. Especially receptors of the ErbB family, including EGFR, ErbB2 (also 
known as HER2/neu)  and ErbB3 are present in many cases of breast cancer and have 
become popular therapeutic targets for intervention as well as development of novel 
therapeutic candidates. The best drug in class is the monoclonal antibody, Trastuzumab 
(Herceptin™; Genentech; against ErbB2) or Cetuximab (Erbitux™; Eli Lilly and Company; 
against EGFR) and the tyrosine kinase inhibitors, Lapatinib (Tykerb; Glaxo Smithkline; 
dual EGFR/Her2 inhibitors) or Erlotinib (Tarceva; Genentech; against ErbB2) are currently 
used clinically. For combinatorial approach, antibody-drug conjugates (ADC) are gaining 
popularity. Trastuzumab-DM1 (also developed by Genentech) is an anti-mitotic fungal 
toxin chemically conjugated to anti-ErbB2 monoclonal antibody. An alternative strategy 
involves targeted delivery of conventional chemotherapeutic drugs (such as Doxorubicin, 
Paclitaxel or Campothecin) encapsulated in liposomal or polymer micelle based 
nanoparticles that are conjugated with anti-ErbB2 or anti-EGFR antibodies or ligands are 
being explored at a laboratory and pre-clinical stage. Both approaches use the 
overexpression of EGFR and ErbB2 as addresses to specifically deliver cytotoxic cargo. 
This may be particularly useful as a strategy for overcoming resistance to currently 
approved ErbB-directed targeted therapies. However, for both antibody-drug conjugates 
as well as targeted nanoparticulate drug-delivery systems, the extent of endocytosis of the 
receptor and its distribution between recycling versus lysosomal pathways can limit 
successful delivery of the chemotherapeutic payload into ErbB2 or EGFR overexpressing 
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breast cancers. Considering a scope of thesis, this section is intended to focus on use of 
clinical combination therapy for the treatment of ErbB2-driven breast cancer. Trastuzumab 
is the current first line therapy for ErbB2-driven breast cancer. It is a humanized 
monoclonal antibody that binds to its receptor and inhibits its oncogenic signaling that 
results in ADCC 51-53. Trastuzumab is well established in palliative as well as adjuvant 
treatment of Her2-positive breast cancer. In the neoadjuvant setting, phase II studies 
incorporating trastuzumab reported pCR rates in the range of 18–39% 54-56. In a 
randomized study, Budzar et al. 57 treated patients with 4 cycles of paclitaxel followed by 
4 cycles of FEC (fluorouracil, epirubicin, and cyclophosphamide) with or without weekly 
trastuzumab for 24 weeks. After the inclusion of only 42 patients, a significant difference 
in terms of pCR rate in favour of trastuzumab was observed, and the trial was terminated 
(66.7 vs. 25%; p = 0.02). Although, Trastuzumab in combination with chemotherapy has 
shown effectiveness in many patients, challenges due to intrinsic or acquired therapeutic 
resistance have prompted the development of Trastuzumab-MCC-DM1 (T-DM1; 
Genentech), which is an antibody-drug conjugate (ADC). DM1 is a Maytansanoid (a 
derivative of Maytansine; a Vinca alkaloid), which functions as an antimitotic drug 58,59. 
DM1 is chemically conjugated to Trastuzumab via a non-reducible Succinimidyl-4-
(Nmaleimidomethyl) cyclohexane-1-carboxylate (MCC) crosslinker, which was optimized 
based on a systematic comparison of various reducible and non-reducible crosslinkers in 
in vitro studies (intracellular drug release) and in vivo pharmacokinetics and toxicity 
studies 60-62. While the mechanism(s) of Trastuzumab resistance remains unclear, several 
studies indicate that it is not due to loss of ErbB2 overexpression 63,64; consequently the 
rationale for T-DM1 design was to use ErbB2 as an address to deliver the cytotoxic drug 
specifically to ErbB2-overexpressing breast cancers. T-DM1 demonstrated potent and 
selective activity against a panel of ErbB2 overexpressing breast cancer cell lines 
(including several Trastuzumab-resistant model cell lines) as compared to normal or 
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ErbB2-low cancer cell lines 65,66. Most importantly, the drug exhibited favorable 
pharmacokinetics, low toxicity in mice and also inhibited growth of Trastuzumab-sensitive 
as well as resistant ErbB2-overexpressing human breast cancer cell xenografts in mice 
65. Although it was presumed that the cytotoxicity was a result of internalization of the ADC 
direct data demonstrating internalization of the ADC was lacking. The importance of this 
is underscored by recent studies that have shown that ErbB2 receptor is not efficiently 
internalized 67,68. Given the numerous studies, which suggest that ErbB2 receptor is either 
internalization resistant or rapidly recycles back to the cell surface 67, data on the site of 
action of T-DM1 is critical in order to improve designs for optimizing the intracellular 
delivery of the Maytansanoid. This will especially become important in cases where 
patient-specific mutations or alterations in the activities of regulators of endocytic 
trafficking (discussed above) could potentially cause refractoriness or reduce the efficacy 
of T-DM1. For example, one factor that is hypothesized to contribute to the low rate of 
endocytosis is the constitutive association of ErbB2 with Heat Shock Protein 90 (HSP90) 
68. It has been demonstrated that HSP90 ATPase inhibitors such as 17-
allylaminodemethoxy geldanamycin (17-AAG) induced rapid downregulation of cell 
surface ErbB2 which is mediated by ubiquitin modification of ErbB2 (Zhou, Xu). 
Subsequent work has shown that 17-AAG indeed promotes the delivery of surface ErbB2 
to the lysosome 59,69, an organelle where molecules such as T-DM1 are intended to go. 
Several HSP90 inhibitors are currently in phase I and II clinical trials and could potentially 
be combined with T-DM1. In yet another attempt, NeoSphere, a 4-arm phase II trial 
focused on the effects of combining trastuzumab with taxanes and also pertuzumab. 
Patients were randomly assigned to docetaxel plus trastuzumab, docetaxel plus 
pertuzumab, an alternative Her2-targeting antibody, and docetaxel plus the combination 
of both antibodies or of trastuzumab and pertuzumab alone without a chemotherapy 
backbone, for a total of 12 weeks. While the triple-combination arm yielded highest pCR 
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rates (46%), this study was the first to report a clinically meaningful activity of a 
chemotherapy-free combination regimen in the neoadjuvant setting with a pCR rate of 
17% 70, underscoring the importance of dual Her2 targeted therapy for improved 
outcomes.     
1.2.3.3. Combination therapy in pancreatic cancer 
Pancreatic cancer is one of the most lethal cancers known with extremely poor prognosis. 
It is estimated that 74 percent of the patients diagnosed with pancreatic cancer die within 
the first year of diagnosis, and most diagnosis is done at a much later stage, when cancer 
already shows distant metastasis. Average life expectancy after metastasis is between 
three to six months, and the five-year survival rate is only 2 percent. Since its approval in 
1997, gemcitabine has been the first-line therapy for patients with unresectable locally 
advanced or metastatic disease as it showed benefit over 5-FU 71. However, the response 
is only marginal; one year survival rates are no more than 17 to 23 percent post 
gemcitabine monotherapy 71-73. Since then, efforts have been directed towards 
development of better therapeutic approach to combat the disease. Platinum- and 
Capecitabine- based combination therapy has shown distinct advantages over 
gemcitabine alone 74-76. Yet another study reported the benefits of Gemcitabine with nab-
PTX 77 this study reported significant improvement in survival rates as well as median 
survival times (by 3.4 months over gemcitabine alone). This trend continued in secondary 
end points like progression-free survival, which improved by as much as 31% as 
compared to gemcitabine alone and response rate that almost tripled. All in all, these 
studies show the benefit of combination therapy over gemcitabine alone, especially when 
dealing with advanced stages of pancreatic cancer. FOLFIRINOX, a combination of four 
agents, folinic acid, fluorouracil, irinotecan and oxaliplatin was approved by the FDA in 
2010 72. The rationale for this combination was based on these drugs having a different 
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mechanism of action, and, more importantly, non-overlapping toxicities 78. FOLFIRINOX 
was the choice of treatment by nearly 18% oncologists for patients with metastatic disease 
79. The study compared either gemcitabine or FOLFIRINOX (only in patients that did not 
show preexisting neutropenia) as the first-line therapy and the other as the second-line 
therapy in case of non-responders or recurrences. Platinum compounds were also used 
as the second-line therapy in some cases. The end result obtained showed that first-line 
therapy of with FOLFIRINOX had significant advantages over gemcitabine therapy. In 
cases that could tolerate FOLFIRINOX, an overall improvement in the survival times as 
well as quality of life was noted 80. However, even the toxicities are non-overlapping, the 
cumulative toxicity profile for FOLFIRINOX can become the dose limiting factor. In the first 
trial itself, 50.8% of the patients needed dose adjustment. The common toxicities observed 
with FOLFIRINOX include Febrile neutropenia, Thrombocytopenic 
bleeding, ≥ grade 3 platelets, Grade 2 persistent neurotoxicity, Grade 3 persistent 
neurotoxicity  OR Grade 4 neurotoxicity and many more non-hematological toxicities. Most 
of the toxicities are severe enough to require discontinuation of the treatment or switching 
to lower doses or alternative agents. Thus, although highly effective over gemcitabine 
monotherapy, very few patients actually qualify for FOLFIRINOX therapy and even fewer 
are able to continue it beyond two to three cycles. To find a balance between the need for 
combination therapy and avoidance of dose-limiting toxicities, the alternative has been to 
look at two-drug combinations. As a part of FOLFIRINOX, platinum compounds showed 
significant efficacy. Cisplatin, like all other platinum compounds, acts by damaging the 
DNA. It is known to first get converted into the aqua form within the cell, which happens 
by the replacement of the labile chloro groups with water molecules. This active form is 
then able to form covalently linked adducts with the DNA. This initial assault then goes on 
to activate a series of signaling pathways that ultimately lead to apoptosis and cell death 
81. The DNA adducts thus formed can cause distortion of the DNA and subsequent 
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recognition by various cellular proteins. This leads to problems in DNA synthesis and 
replication and is reported to cause a prolonged G2 cell-cycle phase arrest. However, the 
exact mechanism of activation of the apoptotic pathways remains unclear. On the other 
hand, gemcitabine is a deoxycytidine analog 82,83. Its mechanism of activation involves 
conversion into its triphosphate form, which can then be incorporated into the DNA as a 
false nucleotide. Usually, one more deoxynucleotide can be incorporated into the DNA 
before the synthesis stops. Another minor mechanism of action of gemcitabine is its ability 
to inhibit ribonucleotide reductase, which plays a key role in the repair mechanism of the 
DNA. Many studies report the benefit of administration of gemcitabine prior to that of 
cisplatin; the reason cited for this is the increase in the formation of Pt-DNA adducts when 
the DNA had already been damaged and exposed due to the incorporation of 
deoxycytidine or active gemcitabine 83. The gemcitabine in turn inhibits the repair of the 
formed Pt-DNA adducts as well as reduces the efficacy of nucleotide excision repair by its 
ability to inhibit the action of ribonucleotide reductase 84,85. On the other hand, when Pt 
compounds are administered prior to gemcitabine, the formed Pt-DNA adducts can no 
longer allow for the incorporation of gemcitabine and that leaves no scope for gemcitabine 
to act. This is yet another classic example of how the synergy of action/cytotoxic effect of 
a combination is not a random event, but something that is highly regulated by the 
mechanism of action of the drugs involved. This mechanism of action then forms the 
rational basis for selection of the sequence in which the drugs should be administered for 
optimal efficacy of the combination. In spite of a strong basis for the synergy of action, this 
combination was also found to have a dose-limiting toxicity and therefore offers the 
potential for development of nanoparticle-based formulation approaches that can control 
the sequence of action as well as mitigate toxicities associated with free drugs.         
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1.3 Antibody conjugates for combination therapy 
Antibody-based therapeutics have become an important class of agents for cancer 
therapy. The idea of antibodies as therapeutics stems from the idea of ‘magic bullets’ as 
conceptualized by Paul Ehrlich nearly a century ago and was given a practical and 
adaptable form with the development of the hybridoma technology by Kohler and Milstein 
86, that eventually allowed for the development of highly target specific monoclonal 
antibodies, directed against a specific receptor. Chimeric humanized IgG antibodies 
overcame the challenges associated with the administration of a foreign protein into the 
human body, which involved recognition and clearance by the immune system as a foreign 
substance and resulted in less than adequate therapeutic response 87-89. Most therapeutic 
antibodies are humanized with an IgG1 isotype that is useful for regulation of effect via 
the Fc region based recognition. Current advances in the antibody production technology 
are directed towards the making of antibodies with more specificity and alterations in the 
glycosylation as well as amino-acid sequence for specific tumor antigens.  
 There are several mechanisms by which mAbs can exert therapeutic vary and can 
exhibit more than one mode of action. They can activate the immune system and cause 
cell death via either complement-dependent cytotoxicity of antibody dependent cellular 
cytotoxicity (ADCC). ADCC involves interaction with two cell types at the same time – the 
Fc region binds with Fc domain on the surface of immune cells 90 whereas the 
complementarity determining region binds with its complementary antigen on the target 
cell such as a cancer cell. Although proven to be effective in vitro, ADCC has been difficult 
to find operational in the in vivo setting. Clyne and Ravetch 53 found that deletion of the Fc 
receptor in an Fc-receptor mouse model resulted in diminished antitumor activity of 
clinically effective mAbs. This data suggested Fc receptor interactions play an important 
role in the anticancer activity of these mAbs and speculations revolve around the role of 
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mononuclear phagocytes or natural killer cells as being the effector cell population, and 
an example of this is the antibody rituximab. However, very little infiltration of host 
leukocytes was seen when such mAbs were administered to murine models. Alternatively, 
it may be hypothesized that the immediate effect of such mAb is some damage to the 
tumor that increases tumor antigen presentation and recruitment of a more specific T-cell 
response 91,92. This is known as the ADCC-mediated adaptive immune switch. CDC is 
more commonly seen with IgM, IgG1 as well as IgG3 subclasses. This effect is a cascade 
that is set in motion by the formation of antigen-antibody complexes. The ultimate effect 
is the formation of a membrane attack complex that creates pores in the cell membrane, 
allowing for free passage of water and solutes out of the cell 93. However, one of the most 
prominent modes of action of antibodies in cancer is causing changes in signal 
transduction. Carcinogenesis is usually associated with an overexpression of certain 
growth factor receptors, probably due to the high rate of cellular turnover. The activation 
of signaling of such receptors occurs via the binding of their respective ligands in the 
extracellular space and promotes cell division and survival. Interfering with the signaling 
can help sensitize and/or reverse resistance to chemotherapeutic drugs. By extension, 
antibodies against the EGFR family are some of the most potent agents available. Most 
antibodies physically bloc the receptor binding site and thereby prevent the binding of the 
growth factor on its target receptor, e.g. cetuximab 94 while others like pertuzumab inhibit 
the heterodimerization of the receptor upon binding of ligand to the receptor 95. Antibodies 
are mostly designed to be directed at hampering the signaling that is most crucial to cell 
survival. Within a solid tumor, these can include antigens associated with the tumor 
stroma, like fibroblasts, vasculature or growth factors like VEGF or EGFR.  However, 
monotherapy with mAbs are as prone to development of resistance as those with small 
molecules. However, development of combination therapy centered on mAbs has many 
advantages. mAbs can be used to deliver cytotoxic payloads specifically to the tumor cells, 
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thereby reducing toxicity to healthy tissues (Wu). Antibodies can be used to deliver 
chemotherapeutic agents, radioisotopes or other proteins like enzymes. This dissertation 
focuses on different ways of delivering chemotherapeutic agents using mAbs, viz., ADCs 
and antibody-nanoparticle conjugates. 
1.3.1 Antibody-drug conjugates 
ADCs are conjugates of mAbs to cytotoxic agents that allow for more specific delivery of 
the cytotoxic agents and potentially widen the therapeutic window of the therapeutic 
system. This can be achieved due to the high binding affinity of mAbs to certain antigens 
that are over expressed on malignant cells. In other words, mAbs act as the vehicles for 
the delivery of cytotoxic payloads to cancer cells. ADCs are developed with the aim of 
enhancing therapeutic efficacy by synergy of action between the mAb and the small 
molecule drugs conjugated with it. These small molecule payloads have much higher 
efficacy but lack target specificity. Thus, ADCs serve to combine the best of both the 
worlds 96-98. ADCs can be envisioned as prodrugs also, wherein the cytotoxic agent can 
be cleaved from the linker and released in its active form post internalization of the ADC, 
as guided by the mAb. Therefore, the choice and design of linker is an area of substantial 
research, to ensure the release of the cytotoxic agent only when it is internalized into the 
cancer cells and not in circulation .Before reaching their target cancer cells, the ADCs 
have to cross many hurdles within the circulation. Thus, the mode of action of ADCs is a 
complex process involving multiple steps and different types of challenges at each level 
99. In circulation, the ADC is expected to have a distribution profile similar to that of the 
mAb itself. As mentioned earlier, the chemical stability of the linker is of utmost importance 
in order to avoid the release of the cytotoxic agent in circulation and avoiding damage to 
healthy tissues. At the same time, the most crucial consideration is ensuring that the mAb 
does not lose its binding affinity to the target receptor. mAbs are complex proteins with 
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secondary and tertiary structures formed due to hydrogen bonding, hydrophobic 
interactions and many other such forces. Conjugation of a liner can disturb the delicate 
higher order structure of the mAb and cause it to lose the confirmation necessary for 
antigen binding. Without binding to the target receptor, internalization of the ADC is not 
possible. Upon successful internalization, retention and trafficking to the right subcellular 
compartment is necessary to achieve therapeutic effect. It is also important to achieve 
enough internalization of the ADC to be in the therapeutic range. Given the unpredictable 
nature of internalization kinetics of receptors, the cytotoxic agents chosen are often quite 
potent. This allows for therapeutic effect to be seen even with small amounts of ADCs 
being internalized as well as allows for smaller number of drug molecules to be conjugated 
per mAb. This also helps in increasing the stability of the final ADC construct. However, in 
practicality, the molar ratio of cytotoxic agents to mAb is usually quite high. This excessive 
payload can alter the surface properties of mAb and cause it to be recognized by the 
immune system, this leads to rapid clearance of the ADC from circulation and does not 
allow for effective therapeutic concentration of the ADC to remain in circulation. In general, 
2-4 drugs per mAb are considered to be appropriate 100,101. At the same time, care needs 
to be taken to avoid masking of the antigen binding sites. Given the complexity of this 
process, conjugation of nanoparticles loaded with cytotoxic agents offers an attractive 
alternative strategy. Nanoparticles can be tailored to encapsulate cytotoxic agents of 
different types. More importantly, with limited points of conjugation to the mAb, 
nanoparticles can help deliver much higher number of drug molecules per mAb. This can 
allow for much greater flexibility in terms of adjusting the dose ration between the drugs 
and the mAbs. In spite of these shortcomings, ADCs are a popular choice for combination 
therapy in cancer and several ADCs are either in clinical trials or already approved for use 
by the FDA. Table 1 lists the ADC currently in clinical trials 102.  
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Table 1. Antibody-drug conjugates in clinical trial. BC, breast cancer; EGFR, epidermal 
growth factor receptor; Glycoprotein NMB, hematopoietic growth factor inducible 
neurokinin-1 type (HGFIN); PSMA, prostate-specific membrane antigen; SLC34A2, solute 
carrier family 34 sodium phosphate member 2; STEAP1, six transmembrane epithelial 
antigen of the prostate 1: a membrane protein overexpressed in prostate cancer; TROP-
2, tumor-associated calcium signal transducer 2. Adapted from 102. 
 
1.3.2 Antibody-nanoparticle conjugates 
Out of the many advantages that nanoparticles offer as drug delivery systems, one of the 
most important ones remain the solubilization of hydrophobic drugs without the use of 
toxic cosolvents and most nanoparticles can hold more than one type of drug, thus making 
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them ideal candidates for combination therapy. Several types of nanoparticles are 
currently in clinical trials, but the most popular type remains nanoparticles made from 
polymers. Table 2 lists some of the formulations based on polymeric nanoparticles that 
are in clinical trial for anticancer therapy. These include, but are not limited to, 
polymerosomes, micelles, hydrogels and nanogels 95,103.  
1.3.2.1 Liposomes:   
Liposomes have been widely used for the delivery of chemotherapeutic agents, genes, 
proteins, or any combinations thereof. While natural biolipids impart low stability to 
liposomes, synthetic amphiphilic copolymers help achieve much higher stability. 
Liposomes mimic the natural cell membrane properties, it is relatively easy for liposomes 
to gain entry into the intracellular space 104. Active targeting of liposomes can be achieved 
by conjugation of active ligands ion their surface. PEG is the most commonly used spacer 
that can be functionalized at both ends and conjugate the liposomes to mAbs or other 
targeting ligands 105. Either whole antibodies or specific fragments like Fc or Fab can be 
used to prepare targeted drug delivery systems, while the chemotherapeutic agents can 
be loaded either in the lipid bilayer (for hydrophobic drugs) or in the aqueous interior for 
the hydrophilic drugs. For the therapy of HER2+ breast cancer, HER-2 targeted DOX-
loaded immunoliposomes (MM-302) have been in clinical trials 106-108. Such active 
targeting strategies have shown differential uptake in cancer cells and spared healthy 
tissues from toxicity 109,110. Another example of targeted liposomes in clinical trials is that 
of DOX-loaded PEGylated immunoliposomes targeted with the F(ab’) fragment of a tumor-





Table 2. List of polymeric nanoparticles in clinical trials indicating the phase and type of 





1.3.2.2 Polymerosomes:   
Polymerosomes were developed as the more stable alternatives to liposomes, to 
overcome shortcomings of short circulation half-lives, low drug encapsulation efficiency 
and short storage shelf life. Like liposomes, polymerosomes can also deliver both 
hydrophobic and hydrophilic drug molecules and can be tuned in terms of size, shape, 
permeability, etc 112,113. At the same time, they can encapsulate drugs like PTX and DOX, 
that have opposite solubility profiles, like polymerosomes prepared from pH-sensitive 
degradable copolymers PEG–PTMBPEC [poly(2,4,6-trimethoxy 
benzylidenepentaerythritolcarbonate)] and PEG-PLA 9,114. They can also encapsulate 
superparamagnetic iron oxide into their aqueous cores for diagnostic as well as 
therapeutic functions and can be surface functionalized with the appropriate mAb 84.  
1.3.2.3 Hydrogels and nanogels: 
Nanogels are three-dimensional hydrogel materials in the nanoscale size range formed 
by crosslinked swellable polymer networks with a high capacity to hold water, without 
actually dissolving into the aqueous medium. Nanogels can be composed of a variety of 
naturally occurring polymers, synthetic polymers or a combination thereof. Their 
characteristics such as size, charge, porosity, amphiphilicity, softness, and degradability 
can be fine-tuned by varying the chemical composition of the nanogels. They are mostly 
spherical particles but the current advancement in synthetic strategies allow for the 
fabrication of nanogels of different shapes 103,115,116. The versatility of their architecture 
allows for incorporation of a plethora of guest molecules ranging from inorganic 
nanoparticles to biomacromolecules like proteins and DNA with suitable modifications of 
the materials used for their construction, without compromising their gel-like behavior 117-
123. As the nanogel structure can be readily adjusted to integrate features of different 
materials and, thus, offer advantages for combinatorial encapsulation of drugs with varying 
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physicochemical properties such as small molecules, proteins and nucleic acids. Fahmy 
and coworkers developed liposomal nanogels of drug-complexed cyclodextrins and 
cytokine-encapsulating biodegradable polymers that can deliver small hydrophobic 
molecular TGF-β inhibitor and water-soluble protein cytokine (IL-2) in a sustained fashion 
to the tumor microenvironment 124. They demonstrated that synergistic effects of 
simultaneously delivered IL-2 and TGF-β inhibitor on activation of the innate arm of the 
immune system led to delayed tumor growth and enhanced survival of melanoma tumor-
bearing mice after systemic administration. Similarly, pDNA and proteins were 
successfully co-encapsulated using pH- and temperature-sensitive carbohydrate-based 
nanogels 114. The nanogels had a core–shell structure with a crosslinked hydrophobic core 
that could be loaded with proteins and the shell contained carbohydrate residues that 
allowed for the complexation of DNA. These nanogels were capable of loading larger-
than-normal amounts of cargo by using a heating and cooling cycle. Owing to the ability 
of nanogels to encapsulate high amounts of biomacromolecules and prevent them from 
degradation, they have been also widely explored for the delivery of proteins and peptides. 
In their pioneering work, Akiyoshi et al. reported that the nanogel of self-assembled 
cholesterol-modified pullulan (CHP) forms a complex with various kinds of proteins 
spontaneously, primarily through hydrophobic interactions 125,126. The amount of protein 
complexed by such nanogels depends on the molecular weight and hydrophobicity of the 
protein. The application of polysaccharide-based nanogels for delivering proteins and 
other macromolecular therapeutics has recently been summarized in a review article 127. In 
another interesting work reported by Chen et al. RAFT polymerization was used to prepare 
disulfide crosslinked nanogels based on PEG-b-poly(2-(hydroxyethyl) methacrylate-co-
acryloyl carbonate) for loading (~ 50% wt.) and triggered intracellular release of proteins 9. 
The in vitro release studies showed that release of fluorescently-labeled cytochrome C 
was minimal under physiological conditions while complete release of the protein from 
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nanogel was observed in the presence of 10 mM dithiothreitol over 22 h. Cytochrome C-
loaded reduction-sensitive nanogels demonstrated apparently better apoptotic activity 
than free cytochrome C and reduction-insensitive controls. 
1.3.2.4 Polymeric micelles: 
Polymeric micelles are self-assembled systems made from an amphiphilic copolymer with 
a characteristic core-shell structure, wherein the hydrophilic shell surrounds the 
hydrophobic core. These hydrophobic cores can hold hydrophobic drugs 128. Depending 
on the chemical nature of the polymer used for their preparation, micelles can encapsulate 
drugs via hydrophobic interactions, electrostatic interactions, coordination bonds or even 
covalent linkages. The design of a polymer that can assemble into stable micelles with a 
suitable size, surface charge and drug-loading capacity is a challenging task. Moreover, it 
is essential that after completion of its function of delivering the drugs to the tumor tissue, 
the polymer must degrade, be biocompatible and cause no harm to the healthy tissues of 
the body 95. Very few polymers are currently approved by the FDA for in vivo use due to 
the above constraints and there is scope for more research in the area of development of 
better polymers for preparation of micellar carriers.  
1.3.2.4.1 Preparation, self-assembly and properties of polymeric 
micelles 
The process of self-assembly of amphiphilic block copolymers is governed by a variety of 
factors, including, but not limited to, the method of preparation, temperature of preparation, 
the lengths of constituent blocks, etc 129. In direct dissolution method, the polymer is simply 
mixed with an aqueous medium to form micelles 130. Film rehydration method involves 
formation of a thin film of the polymer by removal of a low boiling solvent from the polymer 
solution and subsequent rehydration of this thin film by water. The dialysis method also 
involves the use of a cosolvent; the solution of the polymer in the organic solvent is 
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dialyzed against water. This leads to the gradual exchange of the cosolvent with water 
and micellization starts once enough water is present to reach the critical micelle 
concentration of the polymer. The size and polydispersity of the micelles depends not only 
on the method employed, but also the type of cosolvent used and the manner I which that 
solvent interacts with the polymer 131. The same method that is used for the preparation 
of the micelle can also be used for drug encapsulation. In most cases, the drugs are also 
readily soluble in the cosolvent used and are spontaneously incorporated into the micelles 
while the polymer chains assemble into micelles. Different methods may yield slightly 
different encapsulation efficiencies and loading capacities; besides, loading capacity can 
also depend on the nature of the drug molecule as well as the initial feed ratio of the free 
drug 132. The corona or shell forming hydrophilic block is most popularly composed of PEG 
to impart stealth properties to the micelles. The hydrophobic block can be composed of a 
variety of entities. The CMC of the value depends on the relative proportion of hydrophilic 
to hydrophobic blocks. For example, if the hydrophilic block length is kept constant and 
the hydrophobic block length is increased, the CMC of the resultant polymers would 
decrease 133. The lower the CMC, the better is the stability of the micelles in vivo. However, 
the disassembly of the micelles into unimers is crucial for drug release and subsequent 
clearance of the polymer from the body 134-137. One of the most important of any 
nanocarrier system that dictate the in vivo performance is the size. Smaller the size of the 
micelles, farther they can penetrate into the tumor. Moreover, a larger size also causes 
faster and higher clearance of the micelles from circulation by the RES system. Like the 
rest of the parameters, size is also a function of the ratio of the hydrophilic to hydrophobic 
blocks of the constituent polymer 128,138. The uniformity of the starting polymer dictates the 
polydispersity of the micelles thus formed. A narrow size distribution is important to 
achieve more predictable and consistent pharmacokinetic profile of the micelles upon in 
vivo administration 129,139.           
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1.3.2.4.2 Micelles as drug delivery systems 
Multi-drug delivery is very often realized by the step-wise physical loading of an anticancer 
agents in a polymeric micelle. Multi-drug polymeric micelles may release physically loaded 
drug(s) by disassembly of polymeric micelles in blood and/or by diffusion. Drug release 
tends to be rapid in vivo, and in vitro results must be interpreted with caution due to poor 
in vitro/in vivo correlation. Thus, while EPR targeting of solid tumors is feasible with 
physically loaded drug, it is regarded as challenging, and research on multidrug polymeric 
micelles for tumor targeting deserves more attention. Another way for multi-drug loading 
is via chemical conjugation, a reversible covalent linkage is required between an 
anticancer agent and a block copolymer. Drug release from multi-prodrug polymeric 
micelles may occur by simple hydrolysis or stimuli- /environment dependent release and 
may be tuned by choice of chemical linkage, e.g., esters, and spacer groups 46,140. Shin et 
al attempted to physically co-incorporate three hydrophobic drugs, PTX, rapamycin, and 
17-AAG in Poly(ethylene glycol)-block-poly(d,l-lactic acid) (PEG-b-PLA) micelles using a 
simple solvent evaporation method in various drug(s)-in-micelle combinations (Fig. 5) 141. 
Three drug-loaded PEG-b-PLA micelles had a 10–10,000-fold increase in aqueous 
solubility of PTX, rapamycin, and 17-AAG (up to 7.2, 3.3, and 7.3 mg/mL, respectively). 
PEG-b-PLA micelles delayed release of three drugs compared to single drug-loaded 
micelles in vitro. Simultaneous delivery of PTX, rapamycin, and 17-AAG via 3-in-1 PEG-
b-PLA micelles (particle size of ca. 30–40 nm) at 60, 30, and 60 mg/kg, respectively IV 
injection caused durable antitumor responses in A549 human non-small cell lung cancer 
and MDA-MB-231 human breast cancer xenograft models with acceptable acute toxicity. 




Figure 5. Multi-drug loaded PEG-b-PLA micelles for the delivery of PTX, 17-AAG and 
rapamycin. Adapted from 141. 
etoposide, mitomycin-C, doxorubicin and PTX by determination of in vitro cytotoxicity to 
CT-26 colorectal tumor cells or in vivo following a subcutaneous transplant in BALB/c 
mice. Single agent and combination in vivo studies were performed using drug-loaded 
polymeric micelles composed of poly(γ-benzyl l-glutamate) and poly(ethylene oxide) 
(GEG) or poly(l-lactide)/poly(ethylene glycol) (LE) diblock copolymer. When tumor cells 
were exposed to doxorubicin concurrently with etoposide or paclitaxel, evidence of 
synergy was observed in CT-26 cells in vitro. Doxorubicin and paclitaxel loaded into GEG 
or LE copolymers at a high concentration (19.5 and 16.7 wt%, respectively) were almost 
completely released (83.2% and 93.7%, respectively) by day 3. When tumor-bearing mice 
were treated in combination with doxorubicin–paclitaxel or doxorubicin–etoposide, 
substantial antitumor activity was evident compared with single therapy. These data 
suggest that chemotherapy using micelle-loaded anticancer drugs represents a promising 
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potential as a carrier system in modulating drug delivery. In another study, Wang at al 
reported core-shell-type micelles that were doubly emulsified from an amphiphilic 
copolymer methoxy poly(ethylene glycol)-poly(lactide-co-glycolide) (mPEG-PLGA) 142. 
These micelles offered advantages over other nanocarriers, as they were easy to fabricate 
by improved double emulsion method, biocompatible, and showed high loading efficacy. 
More importantly, these micelles could co-deliver hydrophilic doxorubicin and hydrophobic 
PTX. The drugloaded micelles possessed a better polydispersity, indicating that they are 
more readily subject to controlled size distribution. Co-delivery nanocarrier suppressed 
tumor cells growth more efficiently than the delivery of either doxorubicin or PTX at the 
same concentrations, indicating a synergistic effect. Moreover, the drug-loaded micelles 
with a DOX/PTX concentration ratio of 2:1 showed the highest anti-tumor activity to three 
different types of tumor cells. Kabanov and collaborators reported amphiphilic poly(2- 
oxazoline)s (POx)-based micelles as a promising high capacity delivery platform for 
multidrug cancer chemotherapy 143. A variety of binary and ternary drugs combinations of 
PTX, docetaxel, 17-AAG, etoposide and bortezomib were solubilized in defined polymeric 
micelles achieving unprecedented high total loading capacities of up to 50 wt% drug per 
final formulation. Multi-drug loaded POx micelles showed enhanced stability in comparison 
to single-drug loaded micelles. Drug ratio dependent synergistic cytotoxicity of micellar 
etoposide /17-AAG was observed in MCF-7 cancer cells and of micellar bortezomib /17-
AAG in MCF-7, PC3, MDA-MB-231 and HepG2 cells. Katragadda et al developed a 
micellar nanocarriers for concomitant delivery of PTX and 17-AAG for cancer therapy 
(Katragadda). PTX and 17-AAG were simultaneously loaded into polymeric micelles by a 
solvent evaporation method. Two candidate nanocarrier constructs, PEG–PLA-based 
micelles and PEGdistearoylphosphatidylethanolamine/ tocopheryl polyethylene glycol 
1000 (PEGDSPE/ TPGS)-based mixed micelles, were assessed for the release kinetics 
of the loaded drugs. Compared to PEG–PLA micelles, entrapment of paclitaxel and 17-
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AAG into PEGDSPE/ TPGS mixed micelles resulted in significantly prolonged release 
half-lives. Paclitaxel/17-AAG-loaded PEG-DSPE/TPGS mixed micelles were as effective 
in blocking the proliferation of human ovarian cancer SKOV-3 cells as the combined free 
drugs. There are plenty of other examples of use of micelles a carrier of drug 
combinations. This section only covers the most relevant examples. For detailed 
information about the application of polymeric micelles as a multi-drug vehicles, please 
see the review by Cho et al 144. 
1.3.2.5. In vivo behavior of nanoparticles  
Nanoparticles are macromolecular systems specifically designed to achieve long 
circulation half-lives of their cargo in vivo, along with their ability to deliver this cargo at the 
desired site. To realize this, a nanogel, or any nanoparticulate system has to overcome 
many barriers, especially when administered via routes other than intravenous, like oral, 
intradermal, pulmonary, intraocular, etc. Depending on the route of administration, 
nanoparticles are designed specifically to overcome associated barriers and reach the 
circulation intact. Nanoparticles prolong circulation half-life of their cargo by 1) preventing 
their fast clearance especially in the case of small molecules and 2) prevent quick 
degradation or metabolism which is more relevant for biomolecules. One of the most 
important obstacles to achieving prolonged circulation is opsonization of the nanoparticles 
followed by their clearance via organs of the MPS like liver and spleen, where they are 
taken up by the resident monocytes and macrophages 145. PEGylation of the nanogel 
surface imparts them with ‘stealth’ properties by making the surface more hydrophilic, 
shielding a charge that the core might carry and establishing a steric hindrance for 
interaction with serum proteins, although this is highly dependent on the size of nanogel, 
its shape, molecular weight and surface density of the PEG used 146,147. While PEGylation 
endows nanosystems with long circulation properties and reduces MPS uptake, eventually 
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opsonization and macrophage clearance still occurs 148. A number of studies have 
demonstrated that PEGylation of nanoparticles tends to shift their accumulation towards 
the spleen instead of the liver as compared to their non-PEGylated counterparts 149. A 
unique feature that helps nanoparticles partially escape splenic filtration process is their 
softness and deformability. This is can be explained by an example in nature, namely 
erythrocytes, which in spite of having a size range in microns are easily able to pass 
through the splenic filtration bed that has a pore size of few hundred nanometers, due to 
their flexibility and deformability 147,150. In fact, old RBCs are cleared from circulation mainly 
because they lose their flexibility. This biomimetic property of the nanoparticles can be 
highly advantageous for their in vivo application. For example, Lyon and colleagues have 
recently reported that soft spherical acrylamide-based nanoparticles deform and pass 
through membrane pores several times smaller than their hydrodynamic diameter under 
physiological pressures 151. Also, varying the moduli of similar nanoparticles has been 
shown to affect their mechanism and rate of uptake in macrophages 152. Merkel et al. 
reported that decreasing the modulus of microgel particles altered their biodistribution 
properties, allowing them to bypass several organs, such as the lung, that entrapped their 
more rigid counterparts, resulting in increasingly longer circulation times (Merkel). 
Convincing evidence for the prolonged circulation time of soft PEG-based hydrogel 
nanoparticles compared to hard nanoparticles of the same size was recently provided by 
Mitragori and coworkers 153. The deformability of the nanoparticles can be modulated by 
varying the crosslink density within the particle matrix as well as by varying the size of the 
crosslinking moiety 154. Incorporation of electrolyte moieties into the polymer network of 
hydrogel particles to increase the swelling ratio is another straightforward and quite 
efficient way to decrease the modulus 116. However, the distribution of charged groups on 
the surface of a particle can accelerate the clearance of particle. To address this 
drawback, DeSimone's group has recently developed a strategy to generate highly-
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swollen polyelectrolyte gel particle with near-neutral charge while retaining charged group 
in the interior 9. Fraction of nanoparticles that escapes clearance by the mechanisms 
discussed above is then distributed into various organs by the circulating blood. 
Nanoparticles are usually too big to pass through the tight junctions of the normal 
endothelium but can efficiently accumulate in solid tumors or inflamed tissues that have 
unique structural features such as defective leaky and loosely compacted vasculature and 
impaired lymphatic drainage leading to the well-characterized enhanced permeability and 
retention effect (EPR) 155,156. In addition to EPR, bioconjugation of nanoparticles to 
targeting ligands allows directing them to specific receptors or molecules differentially 
overexpressed on the diseased cells/tissues thus improving their retention at the targeted 
site as well as facilitating their cellular uptake 157. Various small molecules, peptides, 
aptamers, antibodies or antibody fragments have been explored for targeted delivery of 
nanoparticles and other nanomedicines in tissue- or cell-specific manner 158. Ligand-
mediated targeting influences the overall biodistribution profile of the nanoparticles as 
compared to their nontargeted counterparts and the bias of distribution is towards to those 
tissues that have a high expression of the receptor. This can help avoid excess 
accumulation of the nanoparticles at off target sites and reduce the associated side 
effects. After extravasation from the blood compartment, nanoparticles have to diffuse 
through the tissue matrix in the interstitial space 159 and reach the targeted cells, where 
they are internalized by a number of different endocytotic mechanisms, depending on the 
size, shape, softness, charge and other surface properties of the nanoparticles and the 
type of cells and receptor being targeted. Internalization of the nanoparticles can occur via 
more than one pathway, making it a highly complex process. But in general, endocytosis 
eventually confines the particles into intracellular vesicles, from where they are trafficked 
into endosomes and ultimately lysosomes. At each of these stages, nanoparticles are 
exposed to varying pH of endosomal/lysosomal lumen, degrading enzymes or reducing 
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environments, which are often utilized as stimuli for the release of cargo held within the 
nanoparticles. Nanogel carriers can also be designed to target specific intracellular 
organelles or escape them, depending on the type of cargo that they carry. For example, 
it is essential for the nanoparticles to undergo endosomal/lysosomal escape so that the 
encapsulated siRNA or oligonucleotides can be released in their active form in the cytosol 
where they are supposed to show their therapeutic effect 118. This has brought growing 
interest in the use of nanoparticles made of bioresponsive polymers to promote escape 
by osmotic effects, membrane binding or membrane fusion or using pH-sensitive or 
reducible crosslinkers to facilitate nanogel destabilization following internalization and 
enhance delivery efficiency 114,160,161. Degradability of the nanoparticles is also essential 
to minimize toxicities associated with the accumulation of the carrier in the body. 
1.4Conclusion 
Polypeptides have an inherent property to assemble into supramolecular structures in 
solution. The formation of supramolecular structures is a controlled and organized process 
that depends by and large on the nature of the polypeptide and conditions of the solvent 
it is exposed to. Formation of amphiphilic copolymers based on such polypeptides can 
allow for tailoring the assembly process to a predefined nanoscale supramolecular 
structure, which can then be used as drug delivery vehicles. The overall process of self-
assembly of such amphiphilic copolymers can then be regarded as a complex 
phenomenon of structural organization that is governed by the nature of constituent 
hydrophilic and hydrophobic blocks, their relative lengths, as well as properties of the 
solvent-phobic block that is the driving force for self-assembly. The inherent 
biocompatibility and biodegradability of polypeptides is of additional advantage for their 
biological applications. For the purpose of the current study, amphiphilic block copolymer 
with following composition was chosen: polyethylene glycol (PEG) as the hydrophilic, 
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stealth imparting block and polyleucine (PLeu) as the hydrophobic part and the initiator of 
micelle formation in aqueous environment. The variables explored in the current study 
were altering the ratio of lengths of constituent blocks as well as chirality of PLeu block 
and the temperature of solvent used for preparation of micelles via the film rehydration 
method. The impact of all these variables on the thermodynamic stability as well as type 
of secondary structures formed and the influence of these attributes on the ability of the 
micelles to encapsulate a combination of hydrophobic drugs into their core are also 
described. The primary purpose of designing this micellar carrier was for combination 
therapy of ErbB2 positive breast cancer. The receptor tyrosine kinase, ErbB2 is a viable 
target in 20-25 % breast cancer patients due to its overexpression. Its degradation is 
associated with slower progression of the disease and increased survival times. While the 
monoclonal antibody Trastuzumab (Herceptin™) is the first line therapy in such patients, 
monotherapy with Trastuzumab has shown little benefit and therefore must be given with 
chemotherapeutic agents. Such combinations also help in delaying the development of 
resistance to Trastuzumab, since multiple cellular pathways can be targeted 
simultaneously. ErbB2 is a client protein of heat shock protein 90 and 17-N-allylamino-17-
demethoxygeldanamycin (17-AAG) is a potent inhibitor of HSP90. Previous work in our 
lab has demonstrated strong synergy of action between 17-AAG and a model cytotoxic 
agent doxorubicin. In order to further improve the efficacy of the therapy, our goal was to 
replace doxorubicin with a more potent, clinically relevant agent paclitaxel (PTX), which 
has been shown to have strong synergistic antitumor effect with 17-AAG in ErbB2-driven 
breast cancers. Since synergy of such therapy is often sequence and dose ratio specific, 
co-delivery of the drugs via the same vehicle is desirable as well as beneficial. Dual drug-
loaded micelles thus prepared could load 17-AAG and PTX in a ratio 2:1 by weight. The 
formulation showed a high level of synergy on BT-474 cells that express a high amount of 
ErbB2 while the synergy was negligible in ErbB2 low MCF-7 cells. The strong synergy 
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was also observed when the formulation was tested in an orthotopic breast cancer mouse 
model developed using ErbB2 overexpressing BT-474 cells, and an arrest in the growth 
of tumors in animals treated with dual drug-loaded micelles was observed, while both 17-
AAG and PTX were used at sub therapeutic doses of 10 mg and 5 mg equivalents per kg 
body weight. The lower doses also helped avoid toxicity associated with the therapy. We 
also show the importance of simultaneously delivering the two drugs via a single carrier 
system as opposed to cocktail of individual drug-loaded micelles administered at 
equivalent doses, which has a better therapeutic outcome than the cocktail therapy. These 
combination drug-loaded micelles were developed as a platform for chemotherapy with 
Trast. The triple therapeutic system of Trast with combination drug-loaded micelles 
containing 17-AAG and PTX exhibited an even stronger anticancer effect and this system 
was one step further in the process of optimizing a carrier system that can be used for 
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CHAPTER 2  
 
Trastuzumab-Conjugated Polypeptide-Based Carrier System for 
Combination Therapy in Breast Cancer 
2.1 Introduction 
Polypeptides have an inherent property to assemble into supramolecular structures in 
solution. The formation of supramolecular structures is a controlled and organized process 
that depends by and large on the nature of the polypeptide and conditions of the solvent 
it is exposed to. Formation of amphiphilic copolymers based on such polypeptides can 
allow for tailoring the assembly process to a predefined nanoscale supramolecular 
structure, which can then be used as drug delivery vehicles 1-4. The overall process of self-
assembly of such amphiphilic copolymers can then be regarded as a complex 
phenomenon of structural organization that is governed by the nature of constituent 
hydrophilic and hydrophobic blocks, their relative lengths, as well as properties of the 
solvent-phobic block that is the driving force for self-assembly 5,6. The inherent 
biocompatibility and biodegradability of polypeptides is of additional advantage for their 
biological applications. For the purpose of the current study, amphiphilic block copolymer 
with following composition was chosen: polyethylene glycol (PEG) as the hydrophilic, 
stealth imparting block and polyleucine (PLeu) as the hydrophobic part and the initiator of 
micelle formation in aqueous environment 7,8. The variables explored in the current study 
were altering the ratio of lengths of constituent blocks as well as chirality of PLeu block 
and the temperature of solvent used for preparation of micelles via the film rehydration 
method. The impact of all these variables on the thermodynamic stability as well as type 
of secondary structures formed and the influence of these attributes on the ability of the 
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micelles to encapsulate a combination of hydrophobic drugs into their core are also 
described.   
The primary purpose of designing this micellar carrier was for combination therapy of 
ErbB2 positive breast cancer. The receptor tyrosine kinase, ErbB2 is a viable target in 20-
25 % breast cancer patients due to its overexpression. Its degradation is associated with 
slower progression of the disease and increased survival times 9,10. While the monoclonal 
antibody Trastuzumab (Herceptin™) is the first line therapy in such patients, monotherapy 
with Trastuzumab has shown little benefit and therefore must be given with 
chemotherapeutic agents. Such combinations also help in delaying the development of 
resistance to Trastuzumab, since multiple cellular pathways can be targeted 
simultaneously. ErbB2 is a client protein of heat shock protein 90 and 17-N-allylamino-17-
demethoxygeldanamycin (17-AAG) is a potent inhibitor of HSP90. Previous work in our 
lab has demonstrated strong synergy of action between 17-AAG and a model cytotoxic 
agent doxorubicin 11,12. In order to further improve the efficacy of the therapy, our goal was 
to replace doxorubicin with the more potent, clinically relevant agent paclitaxel (PTX) 13, 
which has been shown to have strong synergistic antitumor effect with 17-AAG in ErbB2-
driven breast cancers 14,15. Since synergy of such therapy is often sequence and dose 
ratio specific, co-delivery of the drugs via the same vehicle is desirable as well as 
beneficial 16. Dual drug-loaded micelles thus prepared could load 17-AAG and PTX in a 
ratio 2:1 by weight. The formulation showed a high level of synergy on BT-474 cells that 
express a high amount of ErbB2 while the synergy was negligible in ErbB2low MCF-7 
cells. The strong synergy also observed when the formulation was tested in an orthotopic 
breast cancer mouse model developed using ErbB2 overexpressing BT-474 cells, and an 
arrest in the growth of tumors in animals treated with dual drug-loaded micelles was 
observed, while both 17-AAG and PTX were used at sub therapeutic doses of 10 mg and 
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5 mg equivalents per kg body weight. The lower doses also helped avoid toxicity 
associated with the therapy. We also show the importance of simultaneously delivering 
the two drugs via a single carrier system as opposed to cocktail of individual drug-loaded 
micelles administered at equivalent doses, which has a better therapeutic outcome than 
the cocktail therapy. These combination drug-loaded micelles were developed as a 
platform for chemotherapy with Trast. The triple therapeutic system of Trast with 
combination drug-loaded micelles containing 17-AAG and PTX exhibited an even stronger 
anticancer effect, with complete regression of tumors at the end of treatment, which 
reached a palpable size again after day 45 with much slower progression than other 
treatment controls.    
2.2 Materials and methods 
Materials  
PEG-b-PLeu block copolymers with different number of leucine units (7 and 20) were 
synthesized as described below. α-Amino-ω-methoxy poly(ethylene glycol) (mPEG-NH2, 
Mw = 10,000 g mol-1,  Mw / Mn = 1.05) and FMOC-NH-PEG--NH2, Mw = 10,000 g mol-1 were 
purchased from JenKem Technology (TX, USA) and mPEG-NH2,  Mw = 5,000 g mol-1. L-
leucine and D,L-leucine (Leu), 1,2-ethylenediamine, 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDC), paclitaxel, and other chemicals were purchased 
from Sigma-Aldrich (St Louis, MO) and were used without further purification. 
Trastuzumab was obtained from UNMC pharmacy. Fetal bovine serum (FBS), DMEM and 
RPMI 1640 medium, penicillin, streptomycin, Trypsin–ethylenediaminetetraacetic acid 
(EDTA) (0.5% trypsin, 5.3 mM EDTA tetra-sodium) and other chemicals were purchased 
from Invitrogen (Carlsbad, CA, USA). MTT reagent (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) was purchased from Research Products International 
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(Prospect, IL). Cyanine3 (Cy3) carboxylic acid was purchased from Lumiprobe life science 
solutions. All other chemicals were of reagent grade and used without further purification. 
Methods 
N-carboxyanhydride (NCA) of Leu 
D,L or L-Leu (0.015 mol) and anhydrous tetrahydrofuran (THF) were added into a dried 
glass reactor in inert (nitrogen) atmosphere to form a suspension. Triphosgen (0.017 mol) 
was likewise separately dissolved in fresh anhydrous THF and injected drop wise into 
reaction mixture. Nitrogen was bubbled through the mixture during synthesis. The mixture 
was heated at about 55oC with constant stirring till it became transparent. The product was 
precipitated by addition of 5 times excess of n-hexane and then stored at -20oC overnight 
in order to allow complete precipitation of D,L or L–N-carboxyanhydride (Leu-NCA). The 
obtained product was purified further by repeated precipitation with n-hexane, dried under 
vacuum for 24 h and characterized by proton nuclear magnetic resonance (1H-NMR) and 
Gel Permeation Chromatography. 
PEG-b-PLeu block copolymer 
Monoaminomethoxypoly(ethylene glycol) (mPEG-NH2) (0.03 mmol) was dissolved under 
stirring  in 25 mL of anhydrous dimethylformamide (DMF) in nitrogen atmosphere at 30oC. 
Leu-NCA (0.75 mmol, the feed molar ratio of mPEG-NH2 to Leu-NCA was 1: 25) dissolved 
in 5 mL of anhydrous DMF was added dropwise and the solution was stirred for 5 days. 
The aliquot of the reaction mixture was precipitated using excess of diethyl ether, dried 
under vacuum, and the composition of PEG-PBGlu diblock copolymer was determined by 
1H-NMR from the peak intensity ratios of the methylene protons of PEG and the methyl 
protons of the isopropyl groups of Leu (500 MHz in DMSO-d6, 80 ⁰C : 1H NMR [δ = 3.53 
(-CH2- CH2- of PEG), 1.43 – 1.72 {-CH2- CH-(CH3)2}, 0.8 – 0.97 {CH2- CH-(CH3)2} for 
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Leu. The product (PEG-b-Leu) was precipitated by diethyl ether, purified by repeated 
precipitation in diethyl ether and dried under vacuum. By varying the feed molar ratio of 
mPEG-NH2 to Leu-NCA (1:12 and 1:25), copolymers with targeted compositions PEG-b-
PLeu(10) and PEG-b-PLeu(20) were synthesized. Self-assembly behavior of PEG-b-PLeu 
copolymers was examined using pyrene as a hydrophobic fluorescence probe 17. The 
biodegradability of the copolymer was studied upon incubation with Cathepsin B as 
reported previously 18. For conjugation with mAb, polymer was synthesized using FMOC-
NH-PEG--NH2 as the initiator as described above. When the polymerization reaction was 
complete, 10% v/v piperidine in DMF for 1 h was used to deprotect FMOC. The polymer 
was precipitated and washed with diethyl ether, redissolved in DMF and reacted with 4 eq 
of succinic anhydride (SA) overnight. The polymer was purified by reprecipitation and 
washing with ether, dissolved in 70% ethanol in water and subjected to exhaustive dialysis 
against deionized water, followed by lyophilization. For the synthesis of Cy3 labeled 
polymer, Cy3 carboxylic acid was conjugated to polymer prior to deprotection of FMOC in 
DMF and processed as above.   
Preparation of polymeric micelles  
Micelles were prepared by film rehydration method. PEG-b-PLeu copolymer was dissolved 
in acetonitrile (1mg/mL) followed by evaporation of the organic solvent under reduced 
pressure to form a thin film. The film was then rehydrated using hot water (60 ⁰C) and the 
solution was stirred for additional 1h at 60 ⁰C and then cooled gradually to room 
temperature. 
Physicochemical and biophysical methods of characterization 
The 1H NMR spectra for the monomer and copolymers were acquired in DMSO-d6 at 25 
°C and 80 °C respectively using a Bruker Avance III HD NMR spectrometer (500 MHz). 
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Effective hydrodynamic diameters (Deff) of micelles were determined by dynamic light 
scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, UK). All 
measurements were performed in automatic mode at 25°C. Software provided by the 
manufacturer was used to calculate the size, polydispersity indices (PDI), and ζ-potential 
of micelles. All measurements were performed at least in triplicate to calculate mean 
values ± SD. The CD spectra were recorded by using an Aviv circular dichroism 
spectrometer (model 202SF, Aviv Associates Inc., Lakewood, NJ). The spectra were 
measured at 25 °C using a 1 cm path length cell over a wavelength range from 190 to 
260 nm in deionized water. Data were collected at 1 nm intervals with a scan rate of 
15 nm/min. All spectra were acquired in triplicate and averaged. The spectrum of an 
appropriate control sample was then subtracted from each of the sample spectra. The 
final spectral data were converted to mean molar ellipticities. The polymer concentrations 
were 0.02 mM.  
Differential Scanning Calorimetry was used to measure the heat capacity of melting 
transition with a VP-DSC (Microcal, Northampton, MA), using a temperature ramping rate 
of 0.5 ⁰C/min and polypeptide concentration of 0.167 mM. Standard thermodynamic 
profiles were determined using the following equations: ∆GT = ∆Hm (1 – T/Tm) and ∆G = 
∆H – T∆S, where T = 298 K. ∆GT is the free energy at temperature T, ∆Hm is the calorimetric 
enthalpy at transition temperature Tm and ∆S is the unfolding entropy.   
 Molecular weight of micelles was determined using Agilent 1260 Infinity LC system 
equipped with a miniDAWN TREOS multi-angle light scattering (MALS) detector and a 
Optilab T-rEX refractive index detector (Wyatt Technology, Santa Barbara, CA) operated 
in an offline batch mode at a flow rate of 0.5 mL/min using DI water as the mobile phase. 
All analysis was carried out using the software Astra 6.1 (Wyatt Technology), and the 
dn/dc value of PEG (0.162 mL/g) was used for calculations.  
58 
 
Drug loading, conjugation of mAb and drug release 
17-AAG and/or PTX-loaded micelles were prepared by film rehydration method. Briefly, 
polymer and either or both drugs (drug/polymer ratio – 0.8:1) were dissolved in acetonitrile 
and the solvent was evaporated to form a thin film. This film was rehydrated with hot water 
(60 ⁰C) and the solution was stirred for additional 1h at 60 ⁰C and then cooled gradually 
to room temperature. Precipitates of unloaded drugs were removed by centrifugation. 
Drug content was determined by high-performance liquid chromatography (HPLC) 
analysis under isocratic conditions using an Agilent 1200 HPLC system a diode array 
detector set at 227 nm (PTX) and 334 nm (17-AAG). A Nucleosil C18 column was used 
as stationary phase (250 mm  4.6 mm), and mobile phase comprised of acetonitrile/water 
mixture (55/45, v/v) at a flow rate of 1 mL/min. 
Drug-loaded micelles were prepared from SA-modified polymer in the same manner. The 
terminal carboxylic acid was activated by EDC (1.5 molar excess) and Trast was added 
to activated micelles and allowed to react for 2 hours, followed by purification to remove 
unconjugated mAb by SEC. Amount of mAb present in the mAb-micelles conjugate was 
measured by Bradford method using blank micelles as control.  
Drug release from the micelles was examined in PBS (pH 7.4) by dialysis method using a 
membrane with 3,500 Da cutoff. The concentrations of PTX and 17-AAG released were 
determined by HPLC and expressed as a percentage of the total PTX or 17-AAG available 
vs. time. 
Cell culture, cellular association and cytotoxicity assay 
BT-474 and MCF-7 cell lines were obtained from the American Type Culture Collection 
(ATCC) and cultured as described previously 11,12. Cells were harvested with trypsin-EDTA 
(Life Technologies) after 80% confluence. Cells seeded in 96-well plates (5,000 cells/well) 
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24 h prior the experiment were exposed to various doses (0-100 ng/mL on 17-AAG or PTX 
basis) of 17-AAG alone, polymeric micelles alone, 17-AAG-loaded micelles, PTX-loaded 
micelles and (17-AAG+PTX)-loaded micelles for 72 h at 37 °C. Cytotoxicity of drug-loaded 
cl-micelles was assessed by a standard MTT assay 19 and the IC50 values were calculated 
using GraphPad Prism software. Combination index (CI) analysis based on Chou and 
Talalay method 20 was performed using CompuSyn software for 17-AAG and PTX 
combinations, determining synergistic, additive, or antagonistic cytotoxic effects against 
the breast cancer cells. Values of CI < 1 demonstrate synergism while CI = 1 and CI > 1 
values represent additive and antagonistic effects of drug combination, respectively. For 
flow cytometry, cells (50,000 per well) were grown in a 24-well plate 24 hours prior the 
start of the experiment and exposed to Cy3-labeled Trast- or IgG-micelles (25 or 50 µg 
protein per mg polymer) at 37 °C, for 1 or 2 h, washed 3 times with PBS, trypsinized, 
centrifuged (1200 rpm, 3 min) and resuspended in PBS. The % gated cells were analyzed 
using Becton Dickinson FACStarPlus flow cytometer and FACSDiva software (Version 
8.0, Becton Dickinson, San Jose, CA). At least 5000 events were acquired in linear mode, 
gated to exclude debris and dead cells, and visualized in logarithmic mode.   
Animal studies 
Animal model was developed as previously reported (PPGA, trast). All studies were 
performed in strict accordance with the guidelines of University of Nebraska Medical 
Center Institutional Animal Care and Use Committee (IACUC). 4-6 weeks old female 
athymic NCr-nu/nu mice (Taconic Biosciences, NY) implanted with 17-β-Estradiol pellets 
(0.72mg/pellet; 60 day release; Innovative Research of America, Sarasota, Fl) were 
implanted subcutaneously on the lateral side of the neck of the mice three days prior to 
the injection of the tumor cells. 107 BT-474 cells (an ErbB2 overexpressing human breast 
cancer cell line) reconstituted in 50% Matrigel (BD Biosciences, California) in media were 
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injected directly into the mammary fat pad. The animals were randomized into treatment 
groups (n=10) when tumor size reached 100-200 mm3. Drug amount was calculated 
based on the average animal body weight. Treatments were administered by tail vein 
injection, comprising of various treatments as indicated in each specific section of results 
at the same drug ratio at a dose of 10 mg/kg 17-AAG and 5 mg/kg PTX and 6.5 mg/kg 
Trast. Free PTX or free 17-AAG + PTX were formulated using Cremophor-EL: propylene 
glycol: ethanol (2:3:5 by volume) mixture for injections as a component of the free drug 
combination. Tumor dimensions were measured using electronic calipers and tumor 
volume was calculated using the formula V = 0.5 x L x W2 where L: longer dimension and 
W: shorter dimension. Animals were sacrificed when tumor volume was close to 2000 
mm3, greatest tumor dimension was close to 20 mm or tumor became necrotic or animal 
exhibited body weight loss of 20%.   
Apoptosis and proliferation 
Tumors from mice that received different treatments were excised on day 13 (2-3 mice 
per group). The tumors were dissected and fixed in 10% neutral buffered formalin. Then, 
the tissues were processed routinely into paraffin, sectioned at a thickness of 4 μm. 
Proliferating and apoptotic cells were detected using an antibody against Ki-67 and 
caspase-3, respectively. Visualization was done by incubation with DAB+ (brown, for Ki-
67) and Permanent red (for caspase-3) (DAKO) for 2 min. After being rinsed with distilled 
water, the sections were counterstained with hematoxylin. For quantification of Ki-67 and 
caspase-3 expression, the area of positive cells was determined (Image J) in 3 random 
high power fields (10X magnification) and divided by the total area of cells for each field 
of slice. 
Sample preparation and drug content measurement in tissue. 
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Tissue samples harvested from animals sacrificed were frozen and stored at -80 ⁰C until 
further use. Known weights of thawed tissues were homogenized with 3 volumes of HPLC 
grade water using TissueLyser (Qiagen). Calibration curves were built by spiking tissue 
samples from control animals to achieve the final concentration of 5 – 2000 ng/mL. 
Docetaxel was used as an internal standard at a final concentration of 500 ng/mL. 
Homogenates were vortexed for 30 sec, left for 5 mins, then extracted using excess (1 
mL) of ice-cold acetonitrile, vortexed for 3 min and put on a shaker for additional 15 mins. 
All samples were then centrifuged at 16,000 x g for 10 mins and the clear supernatant was 
separated into clean vials and evaporated to dryness followed by reconstitution with 100 
µL of 70% acetonitrile in water (HPLC grade). These samples were run on LC-MS/MS 
system using a Nucleosil C18 column (250 mm4.6 mm) and a mobile phase of 70% 
acetonitrile in water was applied under isocratic conditions at a flow rate of 0.5 mL/min. A 
LC-MS/MS system equipped with triple quadrupole (QTRAP® 6500, Sciex) coupled to 
HPLC system (Nexera X2, Shimadzu) was used in multiple reaction monitoring (MRM) 
mode as follows; m/z 853.995        286 for PTX, 584.07        541 for 17-AAG and  
808.08        527 for docetaxel.  
Blood chemistry and histopathology  
Blood from the sacrificed animals was collected in heparin tubes and analyzed for blood 
cell count and liver and kidney function markers (VetScan Comprehensive Diagnostic 
Profile) using Vetscan VS (Abaxis). Fixed tissues were processed, sectioned, inserted into 
tissue cassettes, dehydrated in 70% ethanol overnight, and paraffin embedded (UNMC 
Tissue Sciences Facility, Omaha, NE). Serial 5 μm sections were stained with either 
hematoxylin or eosin (H&E) or by immunohistochemistry (IHC). For histopathological 
diagnosis, H&E-stained slides were examined by light microscopy and photomicrographs 
were taken using a Nikon camera mounted on a Nikon Eclipse 600 microscope (both 
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Nikon Instruments, Melville, NY) with Adobe Elements 3.0 software (Adobe Systems, San 
Jose, CA).  
Statistical analysis 
Statistical comparisons except animal studies were carried out using Student t-test. For 
the antitumor study and toxicity studies, group means for tumor volume and body weights 
were evaluated using repeated measures analysis of variance with the Bonferroni 
posttest. Survival was estimated using Kaplan–Meier analysis and compared using log-
rank test. P values less than 0.05 were considered significant. Analysis of variance with 
Bonferroni test and Kaplan–Meier analysis with log-rank test were performed using 
GraphPad Prism 5 (GraphPad Software, Inc.).  
2.3 Results 
Synthesis of biodegradable block copolymer PEG-b-PLeu 
The primary objective of this study was to optimize carrier system for hydrophobic drugs 
used in cancer therapy that can be used as a safer substitute to toxic cosolvent currently 
used in clinical practice for such agents. To this end, we chose polypeptide based 
copolymers made from polyethylene glycol and leucine as the hydrophobic block to 
develop micellar carriers for combination of hydrophobic drugs 17-AAG and PTX. The 
block copolymers were synthesized by living ring opening polymerization using amino-
terminated PEG as a macro initiator to polymerize Leu-NCA (Fig. 6). The length of 
polyleucine block was controlled by feed ratio of PEG to Leu-NCA, using a 20% excess 
by weight of Leu-NCA than the targeted block length. Structure of the final copolymer was 
confirmed by 1H-NMR (Fig. 7) and polydispersity by Gel Permeation Chromatography (Fig. 





Figure 6. Scheme for the synthesis and mechanism of PEG-b-PLeu polymer via ring-




Figure 7. 1H- NMR spectrum of PEG-b-PLeu in DMSO-d6, 80 ⁰C 
Characteristic peaks include: δ = 3.53 (-CH2- CH2- of PEG), 1.43 – 1.72 {-CH2- CH-
(CH3)2}, 0.8 – 0.97 {CH2- CH-(CH3)2} for Leu. Repeating units of Leu were calculated 
from the -CH3- proton signal (5.06ppm) of two terminal methyl groups of Leu and the -




Figure 8.  Degradation of PEG228-PLeu20 upon incubation with Cathepsin B at 37 °C, pH 
5.5, as studied by Gel Permeation Chromatography at 0 (black ), 4 (pink), 12 (blue) and 
24 hours (brown) using UV detector at 280 nm.  
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Figure 9. Gel Permeation chromatogram for PEG-b-PLeu synthesized 
using 228 units PEG and Leucine 10 units (magenta) or 20 units 
(black) or PEG (MW: 5000) and 10 units of Leucine (blue). Polymers 
were detected using UV absorbance at 280 nm. 
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cancer cells are known to express an excess of Cathepsin B in the lysosomes. It is a 
cysteine protease that can potentially degrade polypeptides 12,18,21,22. We studied the 
degradation profile of the polymer in presence of cathepsin B using size exclusion 
chromatography (Fig 8). The intensity of the polymer peak diminished over time while that 
of the peaks corresponding to low molecular weight fragments showed a corresponding 
increase, proving that the polymer can be easily degraded by proteases like cathepsin B.  
Optimization of hydrophilic and hydrophobic block lengths of PEG-PLeu  
It is a well-demonstrated fact that the lengths of both hydrophilic and hydrophobic blocks 
play a crucial role in the self-assembly behavior of amphiphilic copolymers and that a 
certain length of the hydrophilic block is needed to provide optimal coverage of the 
hydrophobic block 23-26. Diblock copolymers with different lengths of the hydrophilic PEG 
block and hydrophobic PLeu block were synthesized as described in the previous section. 
The length of polyleucine block was controlled by feed ratio of PEG to Leu-NCA (1:25 and 
1:15). The polymers were characterized by 1H-NMR and Gel Permeation Chromatography 
(Fig. 9) and results are summarized in Table 3. Micelles were prepared from all the 
polymers using the film rehydration technique 27,28. Two different conditions were chosen 
for rehydration: room temperature (RT) and elevated temperature of 60 ⁰C, which is safely 
below the lower critical solution temperature of PEG in water 29. Physicochemical 
characteristics of the micelles prepared under both conditions are listed in Table 4. Only 
the polymer PEG228-b-P(D,L)-Leu20 showed a temperature-dependent change in 
self-assembly behavior that was reflected in nearly 3-fold reduction of the 
hydrodynamic diameter of the micelles prepared by film rehydration at elevated 













    PEG            Leu-NCA      PEG         PLeu            
PEG228-b-P(D,L)-Leu20    0.02                0.5                   228           20              12,263 1.03 
PEG228-b-P(D,L)-Leu10    0.02                0.3             228           10            11,132 1.03 
PEG114-b-P(D,L)-Leu10    0.02                0.3                 114           12   6,358 1.06 
Table 3. Characterization of PEG-b-Pleu block copolymers. 





Sample Deff (nm) PdI 
 RT 60 ⁰C RT 60 ⁰C 
PEG228-b-P(D,L)-Leu10/m 112 158 0.22 0.29 
PEG228-b-P(D,L)-Leu20/m 142 58 0.26 0.12 
PEG114-b-P(D,L)-Leu10/m 141 107 0.27 0.28 
Table 4. Physicochemical characteristics of micelles prepared by film 
rehydration with water at either room temperature (RT) or 60 ⁰C. Hydrodynamic 





lengths of PEG and PLeu were reduced to half while keeping the same weight ratio 
of the two blocks for the polymer PEG114-b-P(D,L)-Leu10. The shorter length of PEG 
was not able to stabilize the assemblies, probably due to the high hydrophobicity 
of the polyleucine block, and our observations show that higher molecular weight 
PEG was essential for the formation of small-sized micelles. In the opposite 
scenario, with the polymer PEG228-b-P(D,L)-Leu10, the length of the hydrophobic 
PLeu block was probably insufficient to drive proper assembly of the resultant 
micelles and showed no temperature-dependent change in self-assembly. In fact, 
when the critical micelle concentration (CMC) of 2 polymers with constant PEG 
length and variable polyleucine length was compared, we observed that increasing 
the PLeu block length from 10 units to 20 units brought down the CMC of 
respective PEG228-b-P(D,L)-Leu copolymers from 1000 mg/L to a mere 15.6 mg/L. 
Similar evidence has been reported previously in the literature 30,31. Thus, in 
conclusion, both the lengths of the composite blocks as well as the thermal 
activation provided by rehydration with water at elevated temperature (60 ⁰C) were 
necessary for the formation of relatively small-sized micelles, making PEG228-b-
P(D,L)-Leu20 give the most favorable micellar assemblies.  
Effect of rehydration temperature on aggregation number of micelles 
To investigate further the effect of rehydration temperature on self-assembly of 
PEG228-b-P(D,L)-Leu20, we determined the aggregation number of micelles 
prepared from PEG228-b-P(D,L)-Leu20 by film rehydration at RT and 60 ⁰C. The 
results are summarized in Table 5. Measurement of molecular weight of the formed 
micelles by static light scattering technique revealed an order of magnitude of   
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Sample Deff (nm) PdI Mw Mn Mw/Mn Nagg 
PEG228-b-P(D,L)-
Leu20/m - 60 ⁰C 
58 0.12 23,58,000 32,70,000 1.39 267 
PEG228-b-P(D,L)-
Leu20/m - RT 
142 0.26 4,60,20,000 3,25,30,000 1.42 2,653 
Table 5. Characterization of PEG(10K)-b-PLeu20 micelles prepared by film rehydration 
at room temperature (RT) or 60 ⁰C. Deff and PdI were measured by Dynamic Light 
Scattering. Mw and Mn were obtained from Static Light Scattering measurement of the 




difference in Mw and Mn as well as the aggregation number (Nagg). Higher 
aggregation number lead to a higher hydrodynamic size of the micelles rehydrated 
at RT. No significant changes were observed in the hydrodynamic diameter as well 
as PdI of these micelles once formed, when subjected to heating at a rate of 0.5 
⁰C on the DLS, from 10 – 65 ⁰C (Fig. S5). This suggests that the polymer chains 
once assembled into micelles have a tight packing of the core with does not change 
upon subsequent heating. Collectively, the data suggests that higher temperature 
helps in better assembly of the polymer chains. The higher temperature can 
increase the mobility of the hydrophobic leucine chains and the enhanced flexibility 
can result in closer packing of the polymer chains. After gradual cooling of the 
micellar dispersion, the structure is locked in place, and subsequent heating does 
not result in any dramatic changes in the hydrodynamic size as well as the PdI of 
these micelles (Fig. 11).  
Optimization of the nature of PLeu block 
It has been shown before that blocks of enantiomerically pure form of leucine can 
assemble into closely packed secondary structures 32. This can have a profound 
effect on the manner of assembly of the polymer as well as the physicochemical 
characteristics of the resultant micelles such as hydrodynamic diameter and drug 
loading capacity and is therefore an important parameter of optimization of amino 
acid based polymers. Having optimized the lengths of the constitutive blocks as 
well as the film rehydration temperature, the next step was to compare the effect 
of nature of hydrophobic block on the properties of micelles. To this end, a control 




Figure 10. Changes in (A) hydrodynamic diameter (Deff) and PdI as a function of 
temperature as measured by dynamic light scattering for PEG-P(D,L)-Leu/m - 60 ⁰C 
(red), PEG-P(D,L)-Leu/m - RT (green) and PEG-P(L)-Leu/m - 60 ⁰C (blue). All 
samples were heated starting from 10 ⁰ – 65 ⁰C and measurements were recorded 




racemic counterpart (20 units of Leu) was synthesized via ring opening 
polymerization. Micelles were prepared from PEG228-b-P(L)-Leu20 via film 
rehydration at 60 ⁰C had a narrow PdI of 0.14  ± 0.03 and hydrodynamic size of 82  
± 2 nm, which was slightly larger than that of PEG228-b-P(D,L)-Leu20/m (58  ± 1) 
prepared in a similar manner. Both types of micelles were further characterized for 
their thermodynamic stability, secondary structure and loading capacities for 
encapsulation of the hydrophobic drugs, 17-AAG and PTX.   
Thermodynamic stability of micelles 
Thermal stability evaluation of preformed micelles by differential scanning 
calorimetry (DSC) revealed quite different thermodynamic profiles for PEG-P(D,L)-
Leu/m and PEG-P(L)-Leu/m, despite both micelles being prepared in the same 
manner. DSC thermograms showed a much sharper transition of melting for PEG-
P(D,L)-Leu/m as compared to PEG-P(L)-Leu/m and also a higher calorimetric 
enthalpy (∆H) and Gibbs free energy (∆GT) of the meting transition. This resulted 
in an entropy value that was half of PEG-P(L)-Leu/m post melting (Table 6). Data 
shown in Fig.11 indicates that all of the melting transitions occur within individual 
micelles, since heating preformed micelles to 65 ⁰C practically did not change the 
hydrodynamic size or the PdI of these micelles. Overall, the thermodynamic 
parameters were indicative of a more cooperative melting transition for PEG-
P(D,L)-Leu/m and mimicked the classic two-state model, with the values of 
calorimetric enthalpy (∆H) and van’t hoff enthalpy (∆Hv) being very close 33,34. As 
opposed to this, thermodynamic parameters for PEG-P(L)-Leu/m were indicative 

















Leu/m - 60 ⁰C 
20,333 298.2 317 ± 0.3 1,209 19,867 -72.25 
PEG-P(L)-Leu/m - 
60 ⁰C 
9,534  320.3 ± 0.2 660.3 29,800 -34.19 
PEG-P(D,L)-
Leu/m - RT 
12,967  321.4 ± 0.7 940.7 29,767 -46.65 
Table 6. Thermodynamic parameters as caculated from the DSC thermograms for 
micelles prepared from PEG-P(D,L)-Leu/m by film rehydration at room temperature (RT) 
or 60 ⁰C or PEG-P(L)-Leu/m at 60 ⁰C.       
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 the characteristics of PEG-P(D,L)-Leu/m prepared by film rehydration at RT, 
indicating that using elevated temperature does not cause any changes in the 
conformation of the P(L)-Leu core unlike the P(D,L)-Leu core. As a further 
confirmation of the high temperature requirement, micelles were also prepared 
from polymer with poly-D,L-Leu block by rehydration and subsequent heating at 
40 ⁰C, and the size and PdI were 114 nm and 0.29 respectively. This further 
supported our initial hypothesis of rehydration at an elevated temperature that 
helps in better interaction between the hydrophobic PLeu segments of the polymer 
and yields closely packed structures with relatively small hydrodynamic diameter.  
Secondary structure 
CD spectrum of preformed micelles from PEG-P(L)-Leu/m showed an α – helical 
secondary structure whereas micelles prepared from PEG-P(D,L)-Leu exhibited a 
random coil behavior in solution (Fig. 12B). When the CD spectrum was recorded 
for both types of micelles at an elevated temperature of 60 ⁰C, no changes were 
observed. This is in line with the DLS data that showed no changes in 
hydrodynamic size and PdI of preformed micelles upon heating (Fig. 11). This 
indicated that, once formed, the core of the micelles retained their secondary 
structure. Also, for PEG-P(L)-Leu/m, this served to show the tightly organized core 
structure and probable rigidity of conformation that prevented close alignment of 
the polymer chains and lead to the formation of micelles with a larger 
hydrodynamic diameter than PEG-P(D,L)-Leu/m (Table 5). No significant changes 
in secondary structure were observed for micelles prepared from either polymer 




Figure 11. (A) Changes in enthalpy as a function of temperature as measured after every 
0.5 oC change in temperature by Differential Scanning Calorimetry for PEG-P(D,L)-Leu/m 
- 60 ⁰C (red), PEG-P(D,L)-Leu/m - RT (green) and PEG-P(L)-Leu/m - 60 ⁰C (blue). (B) 
Changes in secondary structure as measured by circular dichroism spectroscopy at 
different temperatures; micelles were prepared by film rehydration at 60 ⁰C from PEG-
P(L)-Leu and measured at 60 ⁰C (orange) or RT (blue) and from PEG-P(D,L)-Leu, 
measured at 60 ⁰C (red) or RT (green). No significant changes in secondary structure 





Loading and release profile of hydrophobic drugs 
Drug loading into the micelles was carried out using the same method of film rehydration 
used for preparing empty micelles. For drug loading, the film consisted of polymer plus 
either or both 17-AAG and PTX and rehydration led to micelle formation and simultaneous 
encapsulation of the drugs into the hydrophobic core of the micelles. The elevated 
temperature used for rehydration not only leads to increased kinetic mobility of the polymer 
chains in the core but also facilitates its interaction with the hydrophobic drugs and helps 
in their incorporation into the micelles. In case of drug-loaded PEG-P(D,L)-Leu/m, it was 
observed that there was no compromise in the loading capacity when the number of drugs 
increased from one to two (Table 7). Infact, the loading capacity of 17-AAG was nearly 
doubled when it was co-loaded with PTX as has been reported with other systems 
incorporating hydrophobic drugs in the literature, probably due to the presence of one 
hydrophobic drug creating a favorable environment for the incorporation of the other 35. 
Moreover, the micelles showed an intrinsic preference for 17-AAG, and 17-AAG loading 
was always higher than that of PTX, even when the initial feeding ratio of drug to polymer 
was kept same for both the drugs. The increased hydrophobization of the micellar core 
after solubilization of both 17-AAG and PTX led to a slight reduction of the hydrodynamic 
diameter (from 58 nm for empty micelles to 47 nm for 17-AAG + PTX/m). In spite of 
incorporation of almost 10% by weight of hydrophobic drugs, the resultant micelles 
showed no increase in polydispersity index and remained stable in solution for up to 2 
months without signs of aggregation. On the other hand, all of the above attributes were 
absent for drug-loaded micelles prepared from PEG-P(L)-Leu. The loading capacities for 
individual as well as both drugs loaded simultaneously remained much lower than 
corresponding micelles prepared from PEG-P(D,L)-Leu and hydrodynamic diameters 




Table 7. Physicochemical characteristics of drug-loaded micelles after loading of 
drug(s). Deff and PdI were measured by Dynamic Light Scattering. Drug concentrations 
were determined by RP-HPLC. 
  
Polymer Sample Deff






Empty micelles 58  ± 1 0.15  ± 0.01 - 
17-AAG/m 57  ± 2 0.17 ± 0.03 4 
PTX/m 52  ± 1 0.11  ± 0.02 3 
(17-AAG + 
PTX)/m 




Empty micelles 92  ± 2 0.14  ± 0.03 - 
17-AAG/m 85  ± 1 0.18 ± 0.05 2.25 
PTX/m 83  ± 2 0.18  ± 0.01 0.75 
(17-AAG + 
PTX)/m 





P(L)-Leu core is rigid and does not show higher flexibility at elevated temperature. The 
same kinetic rigidity probably prevents adequate interaction between the hydrophobic 
drugs and the core and results in lower loading capacities for the drugs. In conclusion, 
micelles prepared from PEG-P(D,L)-Leu served to be the best carriers for hydrophobic 
drugs.  
The release profile was studied at physiological pH (in PBS) for micelles loaded with one 
or two drugs. The release profiles were nearly the same in both cases and for both the 
drugs (Fig.13). Release profiles were not affected due to the presence of the other drug. 
Practically all of the encapsulated drug was released within 24 hours.   
In vitro cytotoxicity of the drug-loaded micelles 
In vitro cytotoxicity of the free drugs and drug-loaded micelles was tested on two breast 
cancer cell lines with differential expression of ErbB2, BT-474 (ErbB2 high) and MCF-7 
(ErbB2 low). IC50 values are summarized in Table 8. PTX is a known microtubule stabilizer 
and is the standard chemotherapeutic agent used in ErbB2+ breast cancer in combination 
with trastuzumab therapy 36. Herein we studied the synergy of PTX and 17-AAG, which is 
a heat shock protein 90 (HSP90) inhibitor. Among other functions, HSP90 acts as a 
chaperone protein for ErbB2 and inhibition of HSP90 leads to enhanced lysosomal 
degradation of ErbB2 11. Indeed, in the ErbB2 overexpressing cell line BT-474 we 
observed a 1000-fold reduction in the IC50 value of PTX when administered in combination 
with 17-AAG, at a dose ratio of 17-AAG: PTX of 2:1 w/w for 72 hours. Combination index 
analysis at IC50 using the Chou and Talalay method 20 showed a strong synergy between 
the two drugs, both in the form of free drugs (CI = 0.088) and combination in micelles (CI 





Figure 12. Release profile of 17-AAG (●) and PTX (■) when loaded individually (A) or 
simultaneously (B) in the micelles.  
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Sample IC50 (nM) 
 BT-474 MCF-7 
17-AAG 8 ± 0.4 84.5 ± 1.2  
PTX 14.05 ± 0.3 28.4 ± 0.6 
*17-AAG + PTX 
0.043 ± 0.012 
(CI = 0.088) 
62 ± 0.6 
(CI = 0.79) 
17-AAG/m 16 ± 1.3 116.4 ± 1 
PTX/m 31 ± 1 45.3 ± 0.8 
*(17-AAG+PTX)/m 
0.12 ± 0.03 
(CI = 0.083) 
91.5 ± 0.72 
(CI = 0.86) 
17-AAG/m + PTX/m 
0.18 ± 0.12 
(CI = 0.097) 
94 ± 1 
(CI = 0.88) 
Table 8. IC50 values for free drugs and micellar formulations on cell line expressing high 
ErbB-2 (BT-474) and low ErbB-2 (MCF-7) 
*calculated with respect to 17-AAG. CI – combination index, calculated at IC50.  
Ratio of 17-AAG to PTX was c.a. 2:1 w/w.   
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loaded micelles at equivalent doses, the synergy of action was still retained and the effect 
was the same as that seen in case of combination of dual drug-loaded micelles. When the 
same formulations were applied to ErbB2 low MCF-7 cells, the synergy of action was quite 
low, and the CI value was closer to 1, which is indicative of a mere additive effect.  
Antitumor activity of single vs dual drug-loaded micelles   
Antitumor efficacy of the drug-loaded micelles was studied in orthotopic model of ErbB2-
driven breast cancer. 4-week old female athymic nude mice were implanted with BT-474 
cells directly into the fat pad to induce tumor formation according to previously reported 
procedures 11,12. When the tumors reached an average size of 60 – 100 mm3, the animals 
were randomly divided into groups of 10 and treated with either 2 drug-loaded (17-
AAG+PTX)/micelles or cocktail of single drug loaded 17-AAG/micelles + PTX/micelles or 
free PTX or 5% dextrose as control. Treatments were administered in a total volume of 
100 µL every 4th day for a total of 4 injections. The doses of 17-AAG and PTX used were 
10mg/kg and 5mg/kg, which are sub therapeutic doses for each agent (therapeutic i.v. 
doses of 17-AAG and PTX used are 40 and 20 mg/kg body weight, respectively). As 
shown in Fig. 14, only 2-drug regimens were effective in suppressing tumor growth. Free 
PTX showed very little antitumor effect, which is an expected outcome for the sub-
therapeutic dose used. The strong synergy of the 2-drug regimen seen in vitro was also 
seen in vivo, and both combination loaded (17-AAG + PTX)/m as well as cocktail of single 
drug-loaded (17-AAG)/m + (PTX)/m showed significant inhibition of tumor growth as 
compared to control or free PTX groups. Of great interest, however, was the difference in 
activity of the (17-AAG + PTX)/m vs cocktail of single drug-loaded micelles at the same 
dose ratio; tumor suppression in animals treated with (17-AAG+PTX)/m was significantly 
better than those treated with mixture of 17-AAG/micelles + PTX/micelles (P<0.05). This 




Figure 13. In vivo antitumor efficacy of (17-AAG+PTX)/micelles in BT-474 human breast 
cancer xenograft-bearing female nude mice. (A) Relative changes in tumor volume 
measured following intravenous administration of (17-AAG+PTX)/micelles (●) or free PTX 
(■) or 17-AAG/micelles + PTX/micelles (▲) or 5% dextrose (▼) at 10 mg 17-AAG or 5 mg 
PTX equivalents/kg body weight. Drug formulations were injected in100 μL 4 times at 4-
day intervals. Values indicated are means ± SEM (n = 7). (B) Drug content in tumor tissue 
in various treatment groups collected on day 13. Solid bars represent PTX and empty bars 
represent 17-AAG. Data are represented as mean ± SD (n=3). Tumor volume is 







(17-AAG + PTX)/m (17-AAG)/m + (PTX)/m 
Tumor 1.8 ± 0.2 4 ± 0.5 
Liver 1.8 ± 0.2 4 ± 0.5 
Spleen 1.7 ± 0.3 3.5 ± 0.1 
Kidney 1.8 ± 0.1 4.1 ± 0.4 
Table 9. Weight ratio of 17-AAG: PTX in different organs of mice sacrificed on day 14, 




to an altered ratio of the drugs reaching the tumor. Analysis of drug content in the tumors 
of animals (n = 3) sacrificed on day 13 revealed that the ratio of 17-AAG to PTX was 1.8 
± 0.2 (Fig. 14 and Table 9), which is relatively close to the initially administered drug ratio 
of 2:1 by weight. However, in the groupreceiving cocktail of (17-AAG)/m + (PTX)/m, this 
ratio was found to be 4 ± 0.5. When BT-474 cells were treated with ratio of 4:1 in vitro, it 
was found that there was only 10-fold reduction in the IC50 of PTX in combination as 
opposed to the 1000-fold reduction seen when the cells were treated with drugs in the 
ratio of 2:1 and this was also reflected in the CI value changing from 0.088 to 0.47 (Tables 
8 and 10). This further reinforce the importance of spatio-temporal synchronization of 
delivery of the drugs at a defined ratio to retain synergy of action, as was reported in our 
previous work 37.  
Efficacy of therapy 
The efficacy of anticancer therapy was judged by two major parameters: impact on 
survival as well as changes in the population of apoptotic vs proliferating cells in tumors 
at the mechanistic level. Dual drug-loaded (17-AAG+PTX)/m outperformed the cocktail 
therapy with (17-AAG)/m + (PTX)/m in all subsequent analysis. Animals treated with (17-
AAG+PTX)/m had the longest survival times, with only 2 out of 7 animals reaching the 
point of termination in span of 85 days (Fig. 15A). On the other hand, median survival for 
animals treated with cocktail of (17-AAG)/m + (PTX)/m (48 days) was only slightly better 
than free PTX group (42 days) or the untreated control (40 days).  
Excised tumor tissue sections were stained for apoptotic and proliferation markers 
(cleaved caspase 3 and Ki67) and the results are summarized in Fig. 15B and 15C. The 
number of proliferating cells were significantly lower in the tumors of animals treated with 
(17-AAG+PTX)/m as compared with cocktail of (17-AAG)/m + (PTX)/m (P<0.05) or free 




Sample *IC50 (ng/mL) 
Free 17-AAG + PTX 
0.72 ± 0.15 
(CI = 0.47) 
Table 10. IC50 values for free drugs on cell line expressing high ErbB-2 (BT-474). 
*calculated with respect to 17-AAG. CI – combination index, calculated at IC50.  




       
 
Figure 14. (A) Kaplan–Meier analysis of overall survival in 5% dextrose group (1) or free 
PTX group (2) or 17-AAG/micelles + PTX/micelles group (3) or (17-AAG+PTX)/micelles 
group (4). Ki-67-caspase-3 apoptosis assay. Quantification of (B) Ki67 positive and (C) 
caspase-3 positive cells in tumor tissue from mice from various groups. Data are 




treated with (17-AAG+PTX)/m even after 2 weeks of stopping the treatment, while the 
tumors of animals treated with cocktail of (17-AAG)/m + (PTX)/m showed a relatively faster 
rate of progression. Overall, the evidence suggested a strong synergy of anticancer action 
of the combination of 17-AAG and PTX in a ratio-specific manner.  
Toxicity profile 
Having proven the efficacy of the combination therapy, it was also of concern to look at 
the toxicity profile of the treatment. Blood collected from 3 animals sacrificed from each 
treatment group on day 13 was tested for changes in the clinical parameters for hepatic, 
renal and hemopoietic functions. The results are summarized in Table 11. No significant 
changes were observed in any of the markers, which could be attributed to the low dose 
of both agents used. This was of utmost importance for tolerability of the therapy, since 
hepatotoxicity is a dose-limiting side effect of 17-AAG. Safety of the treatment was further 
confirmed at the microscopic level by examination of the H&E stained sections of tissues 
by a pathologist. No changes in the morphology of the organs at the tissue level were 
observed (Fig. 17), except extramedullary hematopoiesis, which was observed in spleens 
of control as well as treated animals and therefore was of no additional health concern. 
Moreover, no changes were noted in the weights of vital organs excised on day 13. 
Another sign of acute toxicity common to most anticancer agents is to the hemopoietic 
system. However, none of the animals showed significant changes in the counts of RBCs, 
WBCs or platelets when whole blood taken from animals on day 13 was analyzed. The 
only sign of side effect was loss in body weight of animals treated with free PTX, which is 
a common effect seen due to the toxic cosolvent Cremophor EL ® used for solubilization 
of PTX. Body weights of animals treated with all micellar formulations remained normal 
















Saline 198 ± 15 53 ± 3 16 ± 0.7 9.4 ± 0.5 1.9 ± 0.6 46 ± 8 
PTX 229 ± 34 62 ± 6 15 ± 2.3 9.2 ± 0.4 2.4 ± 0.4 61 ± 11 
(17-AAG + 
PTX)/m 
179 ± 18 61 ± 2 15 ± 3 8.5 ± 1.3 1.6 ± 0.9 54 ± 12 
(17-AAG)/m + 
(PTX)/m 
186 ± 22 61 ± 8 17 ± 1.7 9.2 ± 0.1 1.4 ± 0.6 33 ± 9 
Table 11. Clinical chemistry parameters and hematocrit of blood samples collected 
from animals sacrificed on day 13 across all treatment groups. Data are 





Figure 15. Relative changes in body weight measured during the course of treatment with 
(17-AAG+PTX)/micelles (●) or free PTX (■) or 17-AAG/micelles + PTX/micelles (▲) or 5% 
dextrose (▼) at 10 mg 17-AAG or 5 mg PTX equivalents/kg body weight. Values indicated 
are means ± SEM (n = 7). Body weights are normalized with respect to body weight at day 
0. ** P<0.01.  
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 Figure 16. Representative H & E stained sections of liver, spleen and kidney of animals 
across different treatment groups. No significant changes in morphology of the organs 




Synthesis, purification and characterization of Trastuzumab-conjugated micelles 
The polymer PEG228-b-P(L)-Leu20 was modified to allow for the conjugation of a targeting 
ligand on the surface. Fmoc-NH-PEG-NH2 was now used as a macroinitiator to polymerize 
(D,L)-Leu-NCA. The modification scheme is described in Fig. 18. Post polymerization, 
Fmoc was removed by piperidine and this deprotection was confirmed by absence of 
Fmoc signals in the resultant 1H-NMR spectrum (Fig. 19). The free amines were then 
conjugated with succinic anhydride to yield free carboxylic acid residues at both ends of 
the polymer and the characteristic peaks were observed in the 1H-NMR spectrum (Fig. 
19). Drug-loaded micelles were prepared by film rehydration technique as described 
above and EDC coupling reaction was used to conjugate free amino group on the side 
chain of lysine residues on Trastuzumab to the activated carboxyl groups on the free 
terminus of PEG corona of the micelles. Unconjugated Trastuzumab was separated from 
Trast-micelle conjugates using size exclusion chromatography (Fig. 20). The mean 
hydrodynamic diameters and polydispersity indices of different micelles are described in 
Table 12. The size of drug-loaded micelles increased by around 20 – 25 nm post 
conjugation of either Trast or IgG, while the polydispersity indices still remained low (< 
0.2). Post surface modification with either IgG or Trast .The loading capacities for 17-AAG 
and PTX, alone or in combination also remained relatively the same as that described in 
the previous section (Table 12).  
Cellular association and cytotxicity 
 Binding activity of Trastuzumab after its conjugation to micelles was studied using flow 
cytometry. Trastuzumab was conjugated to Cy3-labeled micelles at two different surface 
densities – 25 and 50 µg/mg of the polymer and purified as described above. Control 
samples consisted of IgG-conjugated micelles at similar surface densities. It was observed 











Figure 18. 1H- NMR spectrum of PEG-b-PLeu in DMSO-d6, 80 ⁰C through various 




















IgG-(17-AAG+PTX)/m 70 ± 2 0.10 ± 0.01 2.09 ± 0.25  PTX: 3 
17-AAG: 6.5 Trast-(17-AAG+PTX)/m 73 ± 3 0.18 ± 0.02 1.8 ± 0.1 
Trast-(PTX)/m 69 ± 2 0.19 ± 0.02 1.83 ± 0.08 2.8 
Trast-(17-AAG)/m 75 ± 3 0.18 ± 0.01 1.7 ± 0.07 6.2 
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 was significantly higher than the corresponding control IgG-micelles. The uptake of IgG-
micelles, irrespective of the surface density of IgG, remained practically the same over 
time (Fig. 21). On the other hand, Trast-micelles showed increased uptake by BT-474 cells 
in a time-dependent manner, over a period of 2 hours, indicating that Trastuzumab 
retained its binding affinity to ErbB2 receptor even after conjugation to micelles and that a 
surface density as low as 25 µg Trast per mg polymer was sufficient to enhance the uptake 
of micelle in BT-474 cells (Fig. 21).   
The cytotoxic activity of various formulations was tested on both high and low ErbB2 
expressing cell lines, BT-474 and MCF-7 respectively. Presence of Trast led to a 4-fold 
reduction in the IC50 value of the 17-AAG – PTX combination (from 0.08 ± 0.020 to 0.02 ± 
0.015, Table 13). The cocktail of Trast-(17-AAG)/m + Trast-(PTX)/m was similar to that of 
Trast-(17-AAG + PTX)/m, since the overall doses of all 3 therapeutic agents, viz, Trast, 
17-AAG and PTX was the same in both treatment groups. To maintain the same dose of 
Trast, the surface density of Trast used for cocktail was 25 µg per mg polymer for both 
individual drug-loaded micelles, so that their admixture resulted in the same amount of 
Trast as in Trast-(17-AAG + PTX)/m, which had a surface density of 50 µg Trast per mg 
polymer. However, no obvious contribution from Trast was observed in the cytotoxic 
activity of combination of 17-AAG and PTX in the ErbB2 low MCF-7 cells, indicating that 
Trast had both a therapeutic as well as targeting effect that was mediated specifically via 





Figure 20. Cellular association of Cyanine3-labeled Trast/m and IgG/m at two different 
surface densities – 50 and 25 µg protein per mg polymer. Cells were treated with Trast/m 




Sample IC50 (nM) 
 BT-474 MCF-7 
IgG-(17-AAG + PTX)/m 0.14 ± 0.03 97 ± 6  
Trast-(17-AAG + PTX)/m 0.03 ± 0.025 85 ± 8.5 
Trast-(17-AAG) + Trast-(PTX)/m 0.05 ± 0.03 102.4 ± 11 
Table 13. IC50 values for micellar formulations on cell line expressing high ErbB-2 (BT-
474) and low ErbB-2 (MCF-7), calculated with respect to 17-AAG. Ratio of 17-AAG to PTX 




Antitumor activity of Trast-conjugated drug-loaded micelles 
The orthotopic BT-474 xenograft mouse model as described in the previous section was 
used to test the efficacy of Trast-conjugated drug-loaded micelles. Animals were 
administered a total of 4 injections, once every 4th day intravenously via the tail vein. The 
treatment consisted of the vehicle, 5% dextrose or Trast/m or free 17-AAG + PTX in 
Cremophor or IgG-(17-AAG + PTX)/m or Trast-(17-AAG + PTX)/m or Trast-(17-AAG)/m + 
Trast-(PTX)/m at equivalent doses of 6.5 mg Trast, 10 mg 17-AAG and 5 mg PTX per kg 
body weight. Data are representative of 6 animals in each group and curves terminated 
when single animal in the group reached the point of sacrifice. Micellar combination 
therapy with Trast was able to significantly retard tumor growth with respect to control 
animals or animals treated with free drugs. Therapy with Trast alone was also effective in 
retarding tumor growth as compared to vehicle, as the dose of Trast used was within the 
therapeutic window. On the other hand, free 17-AAG and PTX formulated in Cremophor 
had negligible effect on retardation of tumor growth (Fig. 22A), and the progression as well 
as survival (Fig. 22B) remained similar to control animals. Combination loaded IgG-(17-
AAG + PTX)/m were slightly better than cocktail of Trast-(17-AAG)/m + Trast-(PTX)/m in 
terms of tumor progression (not statistically significant) while the survival was significantly 
better than the latter group (P<0.05). However, the best therapeutic outcomes were seen 
in animals treated with combination drug-loaded Trast-(17-AAG + PTX)/m that 
outperformed IgG-(17-AAG + PTX)/m in terms of tumor progression (P<0.001) and 
survival (P<0.01). Tumors regressed at the end of the treatment in this group and reached 
palpable size only after day 45 since the start of the treatment. No animal died from the 
group treated with Trast-(17-AAG + PTX)/m till day 92, whereas the second best response 
was observed in animals treated with IgG-(17-AAG + PTX)/m, with a median survival of 





Figure 21. In vivo antitumor efficacy of (17-AAG+PTX)/micelles in BT-474 human breast 
cancer xenograft-bearing female nude mice. (A) Relative changes in tumor volume 
measured following intravenous administration of 5% dextrose (●) or free 17-AAG + PTX 
(▲) or Trast/m (■) or Trast-(17-AAG)/m + Trast-(PTX)/m (x) or IgG-(17-AAG + PTX)/m 
(▼) or Trast-(17-AAG + PTX)/m (♦) at 10 mg 17-AAG or 5 mg PTX equivalents/kg body 
weight. Drug formulations were injected in100 μL 4 times at 4-day intervals. Values 
indicated are means ± SEM (n = 6). (B) Kaplan–Meier analysis of overall survival in 5% 
dextrose group (1) or free 17-AAG + PTX group (2) Trast/m group (3) or Trast-(17-





Table 14. Median survival (days) and p-values of different treatment regimens with 





p-values (vs. 5% 
dextrose control) 
% survival at 
censoring date  
(92 days) 
5% dextrose 43.5 - 0 
Trast/m 52 0.0151 0 
Free 17-AAG + PTX 45 0.3156 0 
IgG-(17-AAG+PTX)/m 90 <0.0001 22.6 
Trast-(17-AAG+PTX)/m NE <0.0001 100 
Trast-(17-AAG)/m +  
Trast-(PTX)/m 
69 <0.0001 0 
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Drug content in tumor and vital organs post treatment  
Animals were sacrificed (3 each) from treatment groups post 24 and 72 hours of the last 
injection (day 13 and 15 of treatment) and the drug content was measured using an LC-
MS/MS method as described before. This provided insight into total drug accumulation 
immediately at the end of the treatment (24 h after last injection) as well as the clearance 
after 72 fours. Results are summarized in Fig. 23. In animals treated with Trast-(17-AAG 
+ PTX)/m, tumors were practically nonexistent and thus no tumor drug content data from 
this group could be obtained. In general, administration of both 17-AAG and PTX 
encapsulated in micelles lead to significantly higher accumulation (P<0.001) as compared 
to free drugs. While the initial dose ratio for 17-AAG: PTX was 2:1 in all the cases, the 
ratio in which these drugs accumulated into the tumor tissue varied widely (Table 15). For 
free drugs, the ratio was random and variable in all the three animals tested (1.93 ± 0.53). 
The same trend was observed in animals treated with Trast-(17-AAG)/m + Trast-(PTX)/m 
with a ratio of 1.57 ± 0.5 while in animals treated with IgG-(17-AAG + PTX)/m, where both 
the drugs were co-loaded in the same carrier, the ratio was 1.79 ± 0.19. This value was 
found to be much closer to the initial dose ratio of 2:1 and proves the importance of 
synchronized delivery via the same carrier for two drugs that helps in achieving the desired 
ratio of two drugs into the tumor. Both the drugs were washed out from the tumor across 
all treatment groups over time. However, the overall levels of the drug 72 h post last 
injection were still higher in animals treated with micellar formulations, which explains the 
higher therapeutic efficacy in terms of retardation of tumor growth that was seen in these 
groups as compared to free drugs. The accumulation of micellar formulations in organs of 
the MPS system remained higher than free drugs and the accumulation was similar within 
different micellar formulations. The ratio of accumulation in different organs is summarized 
in table 15. 
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Figure 22. Tissue distribution of 17-AAG and PTX in different treatment groups as 
determined LC-MS/MS. Mice were sacrificed and tumor, liver, spleen and kidney were 
harvested 24 h (day 13, fig. A and C) or 72 h after last injection (day 15 of the treatment, 
















24  1.93 ± 0.53 1.79 ± 0.19 - 1.57 ± 0.5 
72  1.74 ± 0.28 2 ± 0.31 - 1.64 ± 0.32 
Liver 
24  1.96 ± 0.19 2.03 ± 0.08 1.97 ± 0.07 1.75 ± 0.7 
72  3 ± 0.61 2.58 ± 0.28 2.11 ± 0.18 1.73 ± 0.26 
Spleen 
24  2.2 ± 0.4 2.03 ± 0.02 1.98 ± 0.13 2.03 ± 0.64 
72  2.46 ± 0.36 2.27 ± 0.05 2.2 ± 0.05 2.25 ± 0.14 
Kidney 
24  2.02 ± 0.17  2.05 ± 0.23 1.9 ± 0.07 2.38 ± 0.72 
72  2.35 ± 0.12 2.38 ± 0.52  2.08 ± 0.3 2.32 ± 0.16 
Table 15. Weight ratio of 17-AAG: PTX in different organs of mice sacrificed 24 h and 72 
h after the last injection (day 13 and 15 of treatment respectively), as measured by LC-





As reported above for the previous animal experiment, 3 animals were sacrificed on day 
13 from each treatment group and was analyzed for changes in clinical markers indicative 
of hepatic, renal and hemopoietic systems. The results are summarized in Table 8. 
Changes in levels of ALP and ALT were seen only in the case of animals treated with 
Trast-(17-AAG)/m + Trast-(PTX)/m and H&E stained sections of livers of 2 out of 3 animals 
showed signs of chronic inflammation. However, other parameters remained normal for 
this group. All of the other micellar formulations were found to be very well tolerated with 
no signs of acute toxicity, both in clinical markers (Table 16) and in morphological 
examination. As opposed to previous study, no weight loss was seen in the animals 
receiving free drugs formulated in Cremophor. This can be attributed to better solubility of 
both drugs (5.2 mg 17-AAG and 2.6 mg PTX per mL) as opposed to 4 mg/mL of PTX 
alone) which reduced the total amount of cosolvent administered per mouse.       
2.4 Discussion 
Combination therapy has become the mainstay of cancer treatment, given the aggressive 
nature of the disease and development of resistance to monotherapy. While it is expected 
that delivering two drugs at their maximum tolerated dose (MTD) would result in a greater 
therapeutic response, often times this is not the case. Examples abound in the literature 
where drugs have been found to have a beneficial effect only at certain dose ratios. When 
used in unfavorable ratios, the effect can be antagonistic, or simply put, the total effect is 
less than that of individual drugs. Moreover, when two drugs are administered systemically 
even at their synergistic ratio, the actual ratio presented to the tumor can vary drastically 
due to differences in their pharmacokinetic parameters like circulation half-life and 
clearance 38. However, when such drugs are administered co-encapsulated in a single 
















Saline 195 ± 11 63 ± 6 16 8.02 ± 0.3 1.5 ± 0.7 66 ± 6 
Free drugs 188 ± 13 72 ± 15 17 ± 1 7.5 ± 0.5 1.8 ± 0.1 65 ± 15 
Trast/m 188 ± 25 64 ± 8 16 ± 3 8.1 ± 0.3 1.9 ± 1.2 63 ± 11 
IgG-(17-AAG + 
PTX)/m 
180 ± 26  62 ± 9 15 ± 3 8 ± 0.2  1.5 ± 0.8 61 ± 11 
Trast-(17-AAG + 
PTX)/m 
184 ± 15 66 ± 8 17 ± 1 7.8 ± 0.3 1.6 ± 0.1 59 ± 3 
Trast-(17-AAG)/m + 
Trast-(PTX)/m 
224 ± 14* 87 ± 7* 13 ± 1 8.3 ± 0.1 2.1 ± 0.4 51 ± 4 
Table 16. Clinical chemistry parameters and hematocrit of blood samples collected from 
animals sacrificed on day 13 across all treatment groups. Data are represented as mean 




the tumor increases tremendously.  One of the primary reasons for administration of higher 
doses or higher frequency of administration is the fast clearance of the small molecule 
drugs. Encapsulation into nanocarriers imparts them macromolecular characteristics. Put 
together, all of these advantages justify the development of nanocarriers tailored to meet 
the demands of ratiometric delivery. Of equal importance with enhanced therapeutic 
efficacy is the avoidance of toxicity. Although encapsulation of cytotoxic agents into 
nanocarriers has shown to reduce the toxicities associated with free drugs, herein we take 
advantage of the high level of synergy to use the therapeutic agents at doses much lower 
than their MTDs that drastically reduces the overall clearance burden on the body for these 
drugs and the synergy of action ensures that the net effect remains much higher than the 
sum of individual effects to maintain the desired therapeutic effect.     
Breast cancer is no exception to the combination therapy approach. The present study is 
focused on ErbB2+ breast cancer, a specific subtype with a prevalence of 20-25 percent 
of all breast cancer cases diagnosed and ErbB2 is well-researched important oncogene 
responsible for progression of the disease 9,10. Trastuzumab, a monoclonal antibody that 
interferes with ErbB2 signaling, remains the mainstay of therapy in clinical practice since 
its approval by the FDA in 1998. However, it is always administered in combination with a 
cytotoxic agent like paclitaxel 36. Paclitaxel being a highly hydrophobic molecule needs 
toxic cosolvents like Cremophor EL for administration, and consequent side effects like 
severe anaphylactoid hypersensitivity reactions, neuropathy and aggregation of 
erythrocytes are well-documented 39. The goal of the present study was to develop a 
nanocarrier to also eliminate the need for such cosolvents. A third agent, 17-AAG, which 
is a model heat shock protein 90 (HSP 90) was also used. 17-AAG has been shown to 
have synergistic anticancer effects with Trast 40 as well as other cytotoxic agents like 
paclitaxel 14,15.  
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A polypeptide based polymer platform, PEG-PLeu was adopted as the biodegradable 
construction material for micelles. Leucine was chosen as the hydrophobic block to drive 
micellization of the polymer chains. The technique of living ring opening polymerization 
was adopted for the synthesis polyleucine block from the reactive amino terminus of PEG. 
This technique yielded polymers with relatively narrow polydispersity (Table 3) 41, which 
in turn lead to the formation of more uniform micelles thereof. In general, the advantage 
of using polypeptide-based polymers is their tendency to form secondary structures, which 
leads to additional stabilization of the resultant micellar assemblies, over and above the 
hydrophobic interactions. Moreover, tweaking the secondary structure by using different 
enantiomeric forms of the amino acids can offer leverage to optimize the polymer’s self-
assembly for desired attributes like better stability and drug holding capacity. However, 
micellization is a complex process governed by other parameters like lengths of the 
constituent blocks as well as the method employed to make micelles. The effect of all 
these variables was investigated in the present study to find the optimal conditions for 
preparation of micelles.  PEG-PLeu polymers with different lengths of PEG and PLeu 
blocks were synthesized and micelles were prepared by the film rehydration technique at 
either room temperature or elevated temperature (60 ⁰C). It is a well-documented fact that 
alteration of the solution conditions can change the way polymers self-assemble 1. High 
temperature of water used for rehydration can lead to thermal activation of the rigid 
hydrophobic polyleucine block, melting it or making it more pliable, leading to a better 
chance of self-assembly than at room temperature 42. When the system is cooled to room 
temperature, the solubility of polyleucine block decreases gradually and results in freezing 
of the structure of the formed micellar aggregates with small size and relatively narrow 
size distribution. While this temerature-dependent alteration in micellar size, molecular 
weight and aggregation number was observed for PEG228-b-P(D,L)-Leu20 (Table 4 and 5), 
alteration in the lengths of constituent blocks negated this effect. This is in conjunction 
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with other studies of amphiphilic diblock copolymers, wherein the authors have noted that 
length of both hydrophilic block and hydrophobic blocks are equally important in the 
formation of uniform micellar aggregates 25,26. When the PEG corona is not long enough 
to stabilize the hydrophobic part, there is an increase in the aggregation number that 
eventually leads to increase in the size of the resultant micelles. In this case, even using 
higher temperatures wasn’t enough to yield smaller micelles. The thermodynamic stability 
of micelles prepared from polymer with P(D,L)-Leu vs P(L)-Leu block was also different, 
along with differences in size and drug loading capacity. Partially, this could be explained 
by looking at the secondary structures of preformed micelles using CD spectroscopy (Fig 
12B). The polymer with enantiomerically pure P(L)-Leu block showed an α – helical 
structure, the intensity of which did not change even upon heating to 60 ⁰C. This rigidity 
in assembly might serve to explain the limited capacity to hold drugs that was exhibited 
by micelles formed from this polymer as opposed to the micelles prepared from polymer 
with P(D.L)-Leu that showed a random coil structure.  
PEG228-b-P(D,L)-Leu20 micelles also showed a higher loading capacity for 17-AAG and 
PTX together (~10% w/w) as opposed to individual drugs (3 – 4% w/w). This has been 
reported on other drug carrier systems in literature 35,43, wherein the presence of multiple 
hydrophobic drugs in the same core did not compromise on the loading capacity of 
individual agents, in spite of them occupying the same space. These micelles showed a 
preference for 17-AAG over PTX, and this caused the drugs to be loaded in the ratio 2:1 
by weight. The increased hydrophobicity due to the presence of two drugs also lead to a 
slight decrease in the size of micelles (Table 7). Since the drugs were physically entrapped 
into the core, the release profiles of 17-AAG and PTX were quite similar, with most of the 
drug being released in the first 24 hours. This release pattern is favorable as previous 
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studies have demonstrated that 17-AAG and PTX in combination have the highest synergy 
of action when administered at the same time 15. 
The cytotoxic activity of free drugs and their micellar formulations revealed a strong 
synergy of action between 17-AAG and PTX only on the cell line over-expressing ErbB2 
(BT-474), whereas in ErbB2-low MCF-7 cells, the cytotoxic effect was additive (Table 5). 
The effect of combination drug-loaded (17-AAG + PTX)/m and cocktail of (17-AAG)/m + 
(PTX)/m remained practically the same.  This similarity can be attributed to the fact that 
both drugs have a similar type of interaction with the hydrophobic core of the micelles and 
therefore a similar release pattern, making the availability of drugs in static, in vitro 
conditions similar for both (17-AAG + PTX)/m and cocktail of (17-AAG)/m + (PTX)/m of 
micelles. Conjugation of Trast to the drug-loaded micelles further increased the potency 
of the overall formulation and IC50 value (calculated with respect to 17-AAG) decreased 
fivefold (from 0.14 ± 0.03 to 0.03 ± 0.025, Table 7).  
Based on the strong synergy and drastic reduction in the IC50 value observed in vitro, 
doses of 17-AAG and PTX selected for testing of the formulation in vivo were in the sub 
therapeutic range (10 mg and 5 mg equivalents per kg body weight). As a result, neither 
PTX alone nor 17-AAG + PTX showed anticancer activity in the free form (Fig 3A and 7). 
As opposed to that, formulations of combination drug-loaded micelles (either (17-AAG + 
PTX)/m or IgG-(17-AAG + PTX)/m) were quite effective in retarding tumor progression as 
compared to control untreated animals. This was also reflected in the increased median 
survival (90 days) of these animals (Fig 4A and 7). Investigation of the amount of drugs 
accumulated into these tumors revealed significantly higher levels of both drugs in case 
of animals that received micellar formulations as opposed to free drugs (Fig. 3B and 8A). 
While combination drug-loaded micelles were able to maintain the initial intended ratio of 
2:1 of 17-AAG: PTX (Table S2 and S6), the ratio in which free drugs accumulated was 
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more random (Table S2). This finding illustrates the utility of micellar drug carriers in 
delivering the desired ratio of drug combinations to target tissues, along with increasing 
total drug accumulation as compared to free drugs due to the well-known enhanced 
permeation and retention effect 37,44. Trast/m without 17-AAG and PTX also had some 
therapeutic activity, and served as further proof in support of the in vitro cell binding assay 
that conjugation of Trast to micelles retained its activity in vivo (Fig 6 and 7). However, the 
best therapeutic effect was seen in animals treated with Trast-(17-AAG + PTX)/m, wherein 
no palpable tumor was present at the end of treatment (day 13), and reached a palpable 
size after day 45 since start of the treatment. Consequently, this group had the best 
survival outcome, wherein all six animals were alive till the last day of survival monitoring 
(day 92). This shows that all the three components, Trast, 17-AAG and PTX have a strong 
synergy of action, and that Trast has both a therapeutic as well as targeting effect which 
would have potentially resulted in highest accumulation of drugs in the tumor that lead to 
complete tumor regression by the end of the treatment. Combination loading of 17-AAG 
and PTX has also played a crucial role in this effect, as was evident from the lower 
therapeutic response when animals were treated with cocktail of Trast-(17-AAG)/m + 
Trast-(PTX)/m, which had all the therapeutic elements at equivalent doses. However, 
accumulation ratios of 17-AAG and PTX were much more skewed in this group (Fig 8A 
and Table S6), indicating that the ratio-specific synergy of action might have been 
mitigated due to the randomness of delivery of the drug cargo. As a result, tumor 
progression in animals treated with cocktail of Trast-(17-AAG)/m + Trast-(PTX)/m was 
similar to animals treated with IgG-(17-AAG + PTX)/m and the median survival was 69 
days. This same trend of combination drug-loaded micelles performing better than cocktail 
of single drug-loaded micelles was also observed in non-targeted formulations (Fig 3), 
further reinforcing the importance of synchronized delivery of drugs to the tumor. This was 
also reflected in a significant difference between the number of proliferating and apoptotic 
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cells (Fig 4B), and both trends were in favor of combination delivery. These observations 
are in line with other examples in the literature wherein ratiometric delivery via the same 
carrier was found to be beneficial over cocktail of single drug-loaded systems 45. 
Accumulation of 17-AAG and PTX in vital organs was also determined (Fig 8). As seen 
with all nanocarriers, drug accumulation in organs of the MPS system (liver and spleen) 
was higher than free drugs. However, both drugs continued to be washed out slowly as 
per the data obtained 72 h after the last injection. This trend was found to be similar across 
all treatment groups, irrespective of the presence of Trast or IgG on the micellar surface. 
Also, the acute toxicity profile observed in targeted and non-targeted micellar formulation 
groups (Table 6 and 8) remained favorable, with the exception of Trast-(17-AAG)/m + 
Trast-(PTX)/m, wherein the livers of 2 out of 3 animals showed signs of chronic 
inflammation upon microscopic examination of H & E stained sections. This was 
consistent with the elevated levels of serum APL and ALT levels in these animals as 
compared to other groups. However, hematocrit of blood samples across all treatment 
groups remained normal and no other vital organs like the spleen, kidney or heart showed 
signs of toxicity, indicating that the therapy was well-tolerated.     
2.5 Conclusion  
The present study demonstrates the importance of biophysical characteristics of core-
forming polyleucine block for the preparation of stable micelles that can load hydrophobic 
drugs. The self-assembly behavior of the block copolymer PEG-PLeu was dictated not 
only by the lengths of both constitutive blocks but also the conditions of preparing these 
micelles. Thin film rehydration at elevated temperature of 60 ⁰C lead to the formation of 
relatively small sized micelles with a low polydispersity index. The nature of polyleucine 
block was also an important parameter for consideration; racemic poly(D,L)-Leu block had 
a smaller hydrodynamic diameter and much higher capacity for encapsulation of 
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hydrophobic drugs as compared to the enantiomeric ally pure poly(L)-Leu block. PEG-
P(D,L)-Leu micelles were able to encapsulate both 17-AAG and PTX in a weight ratio of 
2:1. This ratio showed a high level of synergy of cytotoxic action on ErbB2 overexpressing 
breast cancer cell line BT-474. When tested in an in vivo orthotopic mouse model of breast 
cancer, combination delivery via the same carrier had superior anticancer effect as 
compared to cocktail of individual drug-loaded micelles administered at the same drug 
ratio. Most importantly, marked antitumor effect was seen at a sub therapeutic doses of 
both 17-AAG and PTX, which lead to much better tolerability of the therapy and lack of 
signs of acute toxicity. This combination drug-loaded micellar carrier when conjugated with 
Trast showed complete retardation of tumor growth for prolonged period of time, without 
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Sequential delivery of drugs in pancreatic cancer – a nanoformulation 
approach 
3.1 Introduction  
Pancreatic cancer (PC) is one of the most lethal malignancies, due to aggressive 
tumorigenicity, early metastasis and development of drug resistance to standard care 
chemotherapy. Since its approval in 1997, Gemcitabine (Gem) has been the first-line 
treatment for advanced disease. However, there is no standard second-line therapy after 
Gem failure. FOLFIRINOX, a combination of four agents, folinic acid, fluorouracil, 
irinotecan and oxaliplatin was approved by the FDA in 2010 1. The rationale for this 
combination was based on these drugs having a different mechanism of action, and, more 
importantly, non-overlapping toxicities 2. In cases that could tolerate FOLFIRINOX, an 
overall improvement in the survival times as well as quality of life was noted 3. However, 
even the toxicities are non-overlapping, the cumulative toxicity profile for FOLFIRINOX 
can become the dose limiting factor. In the first trial itself, 50.8% of the patients needed 
dose adjustment. The common toxicities observed with FOLFIRINOX include Febrile 
neutropenia, Thrombocytopenic bleeding, ≥ grade 3 platelets, Grade 2 persistent 
neurotoxicity, Grade 3 persistent neurotoxicity  or Grade 4 neurotoxicity and many more 
non-hematological toxicities. Most of the toxicities are severe enough to require 
discontinuation of the treatment or switching to lower doses or alternative agents. The 
combination of Gem with Cisplatin (CDDP) has been explored in clinical trials for 
metastatic disease. As a part of FOLFIRINOX, platinum compounds showed significant 
efficacy. The combination of Gem with Cisplatin (CDDP) has also been explored in clinical 
trials for metastatic disease. Cisplatin acts by damaging the DNA. It is known to first get 
converted into the aqua form within the cell, which happens by the replacement of the 
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labile chloro groups with water molecules. This active form is then able to form covalently 
linked adducts with the DNA. This initial assault then goes on to activate a series of 
signaling pathways that ultimately lead to apoptosis and cell death 4. The DNA adducts 
thus formed can cause distortion of the DNA and subsequent recognition by various 
cellular proteins. This leads to problems in DNA synthesis and replication and is reported 
to cause a prolonged G2 cell-cycle phase arrest. However, the exact mechanism of 
activation of the apoptotic pathways remains unclear. On the other hand, gemcitabine is 
a deoxycytidine analog 5,6. Its mechanism of activation involves conversion into its 
triphosphate form, which can then be incorporated into the DNA as a false nucleotide. 
Usually, one more deoxynucleotide can be incorporated into the DNA before the synthesis 
stops. Another minor mechanism of action of gemcitabine is its ability to inhibit 
ribonucleotide reductase, which plays a key role in the repair mechanism of the DNA. 
Many studies report the benefit of administration of gemcitabine prior to that of cisplatin; 
the reason cited for this is the increase in the formation of Pt-DNA adducts when the DNA 
had already been damaged and exposed due to the incorporation of deoxycytidine or 
active gemcitabine 6. The gemcitabine in turn inhibits the repair of the formed Pt-DNA 
adducts as well as reduces the efficacy of nucleotide excision repair by its ability to inhibit 
the action of ribonucleotide reductase 7,8. On the other hand, when Pt compounds are 
administered prior to gemcitabine, the formed Pt-DNA adducts can no longer allow for the 
incorporation of gemcitabine and that leaves no scope for gemcitabine to act. Our 
preliminary in vitro studies with the free drugs on T3M4 Simple Cells (COSMC deleted 
cells) showed that synergy of the combination is schedule-dependent, and Gem 
administration followed by CDDP showed the most potent cytotoxic activity. However, this 
combination proved to be only marginally effective in actual practice due to combined 
increased toxicity of both the agents. We have shown that encapsulation of CDDP in 
polymeric nanogels with cross-linked ionic cores enhanced its tumor accumulation and 
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improved its safety profile. Additionally, sustained release profile of CDDP from nanogels 
allows for the administration of free Gem and CDDP loaded nanogels in a single injection 
while still retaining schedule-dependent synergy of the combination. Pancreatic ductal 
adenocarcinoma cells are known to express truncated O-glycans (Tn and STn antigens) 
and it was shown that decorating the nanogels with an antibody directed against this 
antigen further enhanced their uptake by tumor cells while reducing off-target 
accumulation in an in vivo pancreatic cancer model. 
3.2 Materials and methods 
Materials  
PEG-b-PMA di-block copolymer (Mw/Mn = 1.45) was purchased from Polymer Source 
Inc., Canada. The block lengths were 170 and 180 repeating units for PEG and PMA, 
respectively. Maleimide-PEG-amine (Mal-PEG-NH2, MW 7500) was purchased from 
JenKem Technology, USA. Calcium chloride, Ethylenediamine, 1-(3 
dimethylaminopropyl)- 3-ethylcarbodiimide hydrochloride (EDC) 
Ethylenediaminetetraacetic acid (EDTA), 2-Iminothiolane hydrochloride,  were obtained 
from Sigma-Aldrich (St Louis, MO). Gemcitabine hydrochloride and CDDP were also 
purchased from Sigma-Aldrich (St Louis, MO). Serum (FBS) (dialyzed and heat-
inactivated), Dulbecco’s Modified Eagle’s Medium (DMEM), RPMI-1640 medium and 
LysotrackerTM (green) were purchased from Invitrogen Inc. (Carlsbad, CA). MTT reagent 
(3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) was purchased from 
Research Products International (Prospect, IL). All other chemicals were of reagent grade 
and used without further purification.   
Preparation of NGs 
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Polymeric nanogels were synthesized as described previously 9,10. Briefly, PEG-b-PMA 
chains were condensed into complexes using Ca2+ ions as a template (molar ratio of 
[Ca2+]/[COO−] = 1.3) and crosslinked with 1,2 ethylene diamine using EDC chemistry. 
([EDC]/[1,2-ethylenediamine] = 2; [COOH]/[EDC] = 5). Unreacted impurities were 
removed by exhaustive dialysis first against 0.5% aqueous ammonia in the presence of 
100 mM EDTA followed by double distilled water.    
CDDP loading and antibody conjugation to NGs 
CDDP loading was carried out as reported previously 11. Aqueous solution of CDDP 
(1mg/mL) was added to the aqueous dispersion of crosslinked NGs (molar ratio of 
CDDP:[COO−] was 0.5) at pH 9 and incubated at 37 ⁰C for 48h. Unbound CDDP was 
removed by repeated ultrafiltration (MWCO 30,000, Millipore) at 3000 rpm for 15 min. 
Antibody (TKH-2 or non-specific IgG) was thiolated using Traut’s reagent 12,13. Antibody in 
phosphate buffer, pH 8, 10 mM EDTA was allowed to react with 15-fold molar excess of 
2-iminothiolane (Traut’s reagent) for 1 h. Thiolated antibody was purified using Zeba™ 
Spin desalting column previously equilibrated with phosphate buffer, pH 7, 10 mM EDTA 
as per manufacturer’s protocol. Mal-PEG-NH2 (10 eq) was then added to thiolated 
antibody and allowed to react for 2h. Unreacted PEG was removed with repeated 
ultrafiltration (MWCO 30,000, Millipore). The PEGylated antibody was added to dispersion 
of core carboxylate-activated CDDP-loaded NGs (EDC, 1.5 eq of Mal-PEG-NH2) and 
allowed to react for 2h. Unconjugated antibody was purified by size exclusion 
chromatography using Sepharose CL-6B column (Sigma Aldrich), yielding a mixture of 
unmodified and antibody-conjugated NGs 14. Protein content of this mixture was 
determined by microBCA assay kit (Thermo Scientific) using BSA as standard as per the 
manufacturer’s protocol.  
Determination of NG particle size and zeta-potential 
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Intensity-averaged hydrodynamic diameter (Deff) and zeta potential of NGs were 
measured using Malvern Zetasizer (Malvern Instruments Ltd.) at 25 ⁰C, using the 
automatic mode. Each sample was measured atleast in triplicate and software provided 
by the manufacturer was used to calculate size, polydispersity and zeta-potential. Values 
are reported as mean ± SD.   
Cell culture conditions 
T3M4 COSMC KO cells were grown in DMEM media supplemented with 10% FBS and 
transfection with F-Luc-GFP Lentivirus (Capital Biosciences,Rockville, MD) was carried 
out as per manufacturer’s instructions.  
Flow cytometry and CDDP uptake in cells 
Cells (100,000 cells/well) grown in DMEM media in 24-well plates for 24 h were exposed 
to Cy3-labeled TKH-2 - NG or IgG-NG (~ 65 μg protein/mg of polymer) at 37 °C for up to 
2 h, washed three times with PBS, trypsinized, centrifuged (1500 rpm, 5 min) and 
resuspended in PBS (pH 7.4). The % gated cells were analyzed using Becton Dickinson 
FACStarPlus flow cytometer and FACSDiva software (Version 8.0, Becton Dickinson, San 
Jose, CA). At least 5000 events were acquired in linear mode, gated to exclude debris 
and dead cells, and visualized in logarithmic mode.  
In vitro cytotoxic activity 
T3M4 COSMC KO or T3M4 WT cells were seeded in 96-well plates (5000 cells/well) 24 h 
before the experiment and treated with either free Gem or free CDDP or Gem + CDDP or 
Gem, 24 h + CDDP, 24 h or CDDP, 24h + Gem, 24 h or CDDP-NG or Gem + TKH-2 – 
NG/CDDP or Gem + IgG – NG/CDDP at equivalent doses of CDDP (0 – 10 µg/mL or Gem 
0 – 10 ng/mL) for total of 48 h in DMEM at 37 ⁰C followed by washing with PBS and 
maintaining in DMEM with 10% FBS for additional 24 h. Cytotoxicity was determined by 
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standard colorimetric MTT assay 15 and the IC50 values were calculated using GraphPad 
Prism Software. Ratio of CDDP to Gem was c.a. 1140:1 (mol/mol) or 1000:1 w/w.  
Animals and bioluminescence imaging 
All animal studies were conducted in accordance with the protocol approved by the 
University of Nebraska Medical Center Institutional Animal Care and Use Committee. 
Four-week old female nude mice (athymic nude-nu) were obtained from Charles River 
Laboratories and housed in AAALAC accredited facility. Food and reverse osmosis water 
were available ad libitum throughout the study. Animals were quarantined for a week prior 
to the commencement of studies. Imaging was conducted with the in vivo imaging system 
IVIS-200 (Xenogen Corporation, Alameda, CA). Whole-body Imaging was performed as 
reported previously 16. Briefly, animals were anaesthetized with isoflurane (Henry Schein, 
Dublin, OH) prior to imaging. IP injection with D-luciferin (Perkin-Elmer, Waltham, MA) at 
the dose of 150 mg/kg (reconstituted in sterile PBS) was used to generate 
bioluminescence signal. Total bioluminescence signal in the regions of interest (ROIs) 
drawn around the whole abdomen region was quantified using Living Image software 
(version 2.50; Xenogen) and expressed as photons/s/cm2/sr. 
Animal studies 
Pancreatic tumor model was generated by injection of T3M4/Luc cells (~2.5 × 105 cells) 
directly into the pancreas. After development of tumors (14 days after injection) animals 
were randomized (6 treatment groups, n = 10) and treated with 5% dextrose (control) or 
IgG – NG/CDDP or TKH-2 – NG/CDDP or Free Gem or combination of Gem + IgG – 
NG/CDDP or Gem + TKH-2 – NG/CDDP at an equivalent dose of 4 mg/kg CDDP, or 20 
mg/kg Gem. A total of 4 injections were administered via tail vein every 4th day. Animal 
bodyweight and tumor progression, as assessed by BLI, were monitored every fourth day. 
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All images were acquired using identical BLI system settings. All animals were sacrificed 
on day 15 of the commencement of the treatment. Organs and whole blood were collected 
for analysis and peritoneal cavities were checked for the presence of metastasis. 
Sample preparation and Pt content measurement in tissues  
Known weights of thawed tissues collected from sacrificed animals (tumor, kidney, spleen, 
liver and lung, 3 mice per group) were decomposed by wet-ashing in screwcapped vials 
with six volumes of concentrated nitric acid, by heating overnight at 65 °C with constant 
stirring. An iridium internal standard was added prior to digestion. Total platinum 
concentrations were determined by ICP-MS using iridium correction. Calibration range for 
the assay was platinum 2–100 ng/mL with extrapolation to platinum 1000 ng/mL. 
Necessary dilutions were made when the platinum concentration exceeded the calibration 
range. Assay sensitivity was 0.8 ng of Pt/mL, with inter- and intraday assay variability not 
exceeding 5%. 
Blood chemistry and histopathology 
Blood from the sacrificed animals was collected in heparin tubes and analyzed for levels 
of markers for hepatic and renal function using Vetscan VS (Abaxis). Fixed tissues were 
processed, sectioned, inserted into tissue cassettes, dehydrated in 70% ethanol 
overnight, and paraffin embedded (UNMC Tissue Sciences Facility, Omaha, NE).  
Statistical analysis  
Statistical comparisons for in vitro studies were carried out using Students t-test. In animal 
studies, group means BL signal intensity and body weights were analyzed using one-way 
analysis of variance 17. Survival was estimated using Kaplan–Meier analysis and 
compared using log-rank test. P values less than 0.05 were considered significant. 
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Analysis of variance and Kaplan–Meier analysis tests were performed using GraphPad 
Prism 5 (GraphPad Software, Inc.). 
3.3 Results and discussion  
Schedule-dependent cytotoxicity of Gem and CDDP combination 
Gem is the first line therapy for pancreatic cancer since its approval by the FDA in 1996. 
However, development of resistance is a common phenomenon and combination therapy 
is often the alternative. As seen with most combinations, the synergy of action often 
depends on the sequence of administration of the drugs. This is attributed to the different 
mechanisms of actions of the drugs under consideration. Thus, the schedule dependent 
cytotoxic activity of Gem-CDDP combination in the form of free drugs was studied. As 
shown in Table 17 below, the combination was found to be synergistic only when cells 
were exposed to Gem followed by CDDP, with the CI value for this regimen being <1 (CI 
= 0.17). When the CDDP administration was followed by Gem, the effect of the 
combination was antagonistic as the CI value exceeded 1 (CI = 1.98) while co-
administration of Gem and CDDP provided a mere additive effect with CI ~1.  These 
results indicate that a formulation approach involving immediate availability for Gem while 
delayed availability for CDDP would help retain the schedule-dependent synergy of action 
of Gem – CDDP combination. To achieve this, CDDP was formulated in nanogels with a 
sustained release profile with targeting antibody conjugated on the surface of nanogels to 
improve probability of delivery of CDDP to tumor tissue 18. Gem would be administered as 
a free drug, making it available immediately for uptake upon intravenous administration.    
Preparation and characterization of CDDP-loaded, antibody-conjugated NGs 
PEO-b-PMA complexes were made by the condensation of polyion chains of the polymer 




Figure 23 Scheme for the preparation of antibody-nanogel conjugates  
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Treatment schedule IC50 (with respect to CDDP, µg/ml) 
CDDP,24h,Gem, 24h 
1.69 ± 0.052 
(CI = 1.98) 
Gem,24h,CDDP, 24h 
0.028 ± 0.004 
(CI = 0.17) 
CDDP-Gem co-administration 
1.51 ± 0.15 
(CI = 0.95) 
CDDP 1.18 ± 0.14 
aGem 0.48 ± 0.03 (ng/mL) 
Oxaliplatin 2.7 ± 0.33 
Table 17. Comparison of IC50 values for different sequences of administration of Gem 
and CDDP as per MTT assay. T3M4 COSMC KO cells were treated for a total of 48 h. 





   
Sample (pH 7.4) Deff (nm) PdI Zeta potential (mV) 
cl-NG 114 ± 2 0.09 ±  0.02 -25 ± 1.8 
CDDP/NG 93 ± 1 0.1 ± 0.02 -14 ± 1.3 
TKH-2 – NG/CDDP 135 ± 2 0.15 ± 0.02 -9.6 ± 1 
IgG – NG/CDDP 137 ± 1 0.14 ± 0.01 -10.7 ± 2.1 




ethylene diamine lead to the formation of NGs that had a mean particle size of 114 nm. 
Loading of CDDP occurs through co-ordinate bond formation between Pt and COO- ions 
and lead to a reduction in size (Deff = 93 nm) and increase in ζ-potential (from -25 -14 mV). 
The loading capacity for hydrophilic drugs such as CDDP is very high (~30 % w/w) 19,20. 
For conjugation, antibodies (either TKH-2 or IgG) were first thiolated using Traut’s reagent 
and PEGylated using maleimide-PEG-NH2. The free amine of PEG spacer was then used 
to conjugate the antibody to core carboxylate groups of CDDP-loaded NGs (fig.23). Such 
conjugation strategy is non-specific for the site as well as number of PEG spacers 
conjugated per antibody molecule. The resultant mixture of antibody-conjugated and non-
modified NGs was separated from free antibody by size exclusion chromatography using 
a Sepharose CL-6B column. Conjugation of either TKH-2 or IgG lead to a slight increase 
in the size (~ 140 nm). The physicochemical parameters are summarized in Table 18. 
Protein content was ~65 µg/mg polymer for both antibody-decorated NGs, as determined 
by microBCA assay.  
3.1. Cellular interaction of antibody-conjugated NGs 
In order to test whether the conjugation process lead to loss of binding affinity, antibodies 
(TKH-2 or IgG) were conjugated to FITC-labeled NGs as described above and the cellular 
association of the NGs was estimated using flow cytometry. Both T3M4 COSMC KO 
(receptor positive) and T3M4 WT (receptor negative) cells were treated with FITC-labeled 
TKH-2 – NG or IgG – NG. As shown in Figure 24A and Figure 25, the uptake of TKH-2 – 
NG is significantly higher (P < 0.01) than IgG – NG in T3M4 cells while the uptake for both 
types of NGs remains practically the same in T3M4 WT cells (Figure 24B). Also, the 
percentage of parent gated cells positive for TKH-2 – NGs is much higher (P<0.05) when 
T3M4 COSMC KO cells are treated with TKH-2 – NGs vs T3M4 WT cells (Figure 24C). A 





Figure 24. Cellular association of FITC-labeled TKH-2 – NG and IgG – NG on A) T3M4 
COSMC KO cells and B) T3M4 WT cells. C) Percentage of parent gated cells as a function 
of time when T3M4 COSMC KO cells and T3M4 WT cells were treated with FITC-labeled 
TKH-2 NGs. Cells were treated with 0.5 mg/mL polymer in media. Protein content was 65 






































Figure 25. Time dependent cellular association of TKH-2 NG vs IgG – NGs in T3M4 




CDDP-loaded TKH-2 – NG or IgG – NG (Figure 24D). After 1 or 2 h treatment, the cells 
were washed and lysed and the lysates were checked for Pt content by ICP-MS. Pt content 
was significantly higher in T3M4 COSMC KO cells treated with TKH-2 – NG as compared 
with IgG – NG (P<0.05), while both the treatments showed similar Pt levels in case of 
T3M4 WT cells 
In vitro cytotoxic activity of formulation 
Cells (T3M4 COSMC KO and WT) were treated with Gem + TKH-2 – NG/CDDP or Gem 
+ IgG – NG/CDDP or free Gem, 24h + CDDP, 24h or free Gem or free CDDP or NG/CDDP 
or Gem + CDDP co-administration. As seen with many targeted delivery systems 16, the 
uptake of targeted and nontargeted NGs can become practically the same. The same 
effect is expected to be the cause for no significant difference in the IC50 values of cells 
when treated with targeted (TKH-2 – NG) vs nontargeted NGs (IgG – NG). This trend was 
also seen across the receptor negative WT cells. To mimic the sequence in which Gem 
and CDDP were made available to the cells, free Gem was applied to the cells for 24 h 
and CDDP was added to Gem-containing media for the next 24 h at the same final CDDP 
concentration as the formulation. This sequence-dependent application of Gem and 
CDDP resulted in an IC50 value that was approx. 5-fold lower than values seen when cells 
were treated with the formulation, which is observed when transitioning from free CDDP 
to CDDP loaded into NGs 16,21.        
Antitumor activity in orthotopic pancreatic cancer model 
The efficacy of the formulation was tested on an orthotopic pancreatic cancer mouse 
model. Mice were injected with T3M4 COSMC KO/Luc cells directly into the pancreas. 
Tumors were detectable from day 9 by BLI and treatment was started from day 14 post 
inoculation of cells. Animals were treated IV via the tail vein every 4th day for a total of 4  
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Table 19. IC50 values of targeted and nontargeted formulation on T3M4 COSMC KO 




 (w.r.t CDDP, µg/mL) 
T3M4 COSMC KO T3M4 WT 
Gem + TKH-2 – NG/CDDP 0.13 ± 0.014 0.14 ± 0.003 
Gem + IgG – NG/CDDP 0.15 ± 0.007 0.16 ± 0.006 
Gem, 24h + CDDP, 24h 0.03 ± 0.003 0.035 ± 0.002 
a Gem 0.5 ± 0.03 0.8 ± 0.03 
Free CDDP 1.22 ± 0.15 1.55 ± 0.04 
NG/CDDP 6.45 ± 0.30 7.77 ± 0.23 












Figure 26. In vivo tumor progression in orthotopic pancreatic cancer across various 






Figure 27. A) Whole tumor weights from animals sacrificed on day 15 of treatment. B) 






Peritoneum Spleen Liver Lymph 
Nodes 
Diaphragm 
Saline (control) 100 20 60 10 70 30 
CDDP/M IgG 100 10 90 10 70 60 
CDDP/M-TKH2 100 10 50 0 60 50 
Gemcitabine 100 10 80 0 30 20 
Gem/CDDP/M-IgG 100 0 30 0 50 20 
Gem/CDDP/M/TKH2 100 0 40 0 40 10 
   Table 20. Tumor metastasis as observed across different treatment arms.   
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injections at CDDP 4 mg/kg and Gem 20 mg/kg equivalent doses. The tumor progression 
for each individual treatment is shown in Figure 26. Monotherapy with either TKH-2 – 
NG/CDDP (targeted formulation) or Gem was successful in retarding tumor growth 
significantly (P < 0.05). Treatment with Gem + TKH-2 – NG/CDDP further retarded the 
tumor growth as compared with Gem (P < 0.05) and TKH-2 – NG/CDDP (P < 0.01). 
Presence of Gem also caused significant suppression of tumor growth in animals 
treatedwith IgG – NG/CDDP (nontargeted formulation, P < 0.01). While Gem + TKH-2 – 
NG/CDDP was better than Gem + IgG – NG/CDDP, it did not achieve statistical 
significance. The same trend was also observed in weights of whole tumors post necropsy 
of animals on day 15 (Figure 27A). While primary tumor was seen in all animals that were 
inoculated with tumor cells, metastasis was found only in some animals. Notably, 
peritoneal metastasis was not observed in any of the animals (n = 10) that received 
combination of both Gem and CDDP/NG, either targeted or nontargeted (Table 20). 
Pt content in tumor and other organs 
To compare the effectiveness of TKH-2 in delivering CDDP to tumors, tissues from 3 
animals randomly selected from each treatment group were digested and checked for Pt 
content using ICP-MS. It was found that Pt levels in tumors of animals treated with TKH-
2 – NG/CDDP were higher than those treated with IgG – NG/CDDP (P < 0.01) irrespective 
of the presence of Gem (Figure 28). An interesting observation, however, was that the 
presence of Gem itself helped in enhancing the delivery of CDDP to the tumor tissue, as 
could be seen between animals treated with Gem + TKH-2 – NG/CDDP vs TKH-2 – 
NG/CDDP (P < 0.05). High amounts of Pt were also observed in liver and spleen, organs 
of the mononuclear phagocyte system, but the effects of targeted delivery due to TKH-2 
as well as overall enhanced delivery of Pt due the presence of Gem were observed 












Figure 28. Platinum content in various tissues of animals sacrificed on day 15, as 
determined by ICP-MS. Animals were treated with TKH-2 – NG/CDDP or Gem + TKH-2 
– NG/CDDP or IgG  – NG/CDDP or Gem + IgG – NG/CDDP. Data are represented as 























Gem + TKH-2 – NG/CDDP
























Treatment group ALP (IU/L) ALT (IU/L) BUN 
(mg/dL) 
Gem + TKH-2 – NG/CDDP 14.5 ± 0.7 46 17 
Gem + IgG – NG/CDDP 13 ± 2.65 50 ± 3 17.6 ± 1.53 
TKH-2 – NG/CDDP 15 39.5 ± 5.5 15 ± 1.15 
IgG – NG/CDDP 15 38 ± 2.6 15 ± 0.6 
Free Gem 15.5± 2.1 45.5 ± 3 15 ± 4 
Control 14 ± 0.8 46.5 ± 3.5 17 ± 2.8 
Table 21. Clinical chemistry parameters as assessed by whole blood analysis from 




Clinical chemistry parameters and toxicity profiles 
During the course of the treatment, body weights of animals were routinely monitored, and 
no significant changes were observed across different treatment groups (Figure 27 B). 
Blood collected from animals sacrificed on day 15 was subjected to analysis of clinical 
chemistry parameters indicative of renal and hepatotoxicity. As shown in Table 21 below, 
parameters across all treatment groups were comparable to control animals, which 
indicated that no short term toxicity occurred to the animals as a result of the treatment. 
Furthermore, H & E stained sections of all healthy organs were examined under a 
microscope by pathologist. No signs of morphological changes were seen in any of the 
animals, providing additional proof that all treatments were well-tolerated by the animals 
and no short term toxicity was evident. 
3.3 Conclusion 
In this study, we demonstrated that TKH-2 decorated nanogels were effective in delivering 
higher payloads of nanogels encapsulating CDDP. This lead to a better therapeutic 
efficacy in terms of tumor growth retardation as well as avoidance of acute toxicity, when 
tested in an orthotopic pancreatic cancer murine model. The sequential administration of 
Gem followed by CDDP that had the highest synergy was also maintained in vivo for 
enhanced therapeutic efficacy. Most importantly, this formulation approach allowed for the 
administration of both the drugs in the same dose and still achieved sequential 
administration. At the same time, encapsulation of CDDP into tumor-targeted NGs allowed 
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CHAPTER 4  
Summary 
Combination therapy remains the mainstay of therapy for cancer. While combinations can 
be made between various classes of therapeutic agents, the focus of this dissertation 
remained chemotherapy. Monoclonal antibodies have emerged in recent years to target 
specific cellular pathways and have shown promising therapeutic efficacy. However, 
monotherapy always carries a risk of development of resistance and thus our goal was to 
combine the advantages offered by both small molecules and monoclonal antibodies for 
the development of novel combination therapies for cancer. To this end, conjugation of 
nanoparticles loaded with cytotoxic agents to monoclonal antibodies is an attractive 
strategy. Nanoparticles can be tailored to encapsulate cytotoxic agents of different types. 
More importantly, with limited points of conjugation to the mAb, nanoparticles can help 
deliver much higher number of drug molecules per mAb. This can allow for much greater 
flexibility in terms of adjusting the dose ration between the drugs and the mAbs. 
 Polypeptides have an inherent property to assemble into supramolecular structures in 
solution. The formation of supramolecular structures is a controlled and organized process 
that depends by and large on the nature of the polypeptide and conditions of the solvent 
it is exposed to. Formation of amphiphilic copolymers based on such polypeptides can 
allow for tailoring the assembly process to a predefined nanoscale supramolecular 
structure, which can then be used as drug delivery vehicles. The overall process of self-
assembly of such amphiphilic copolymers can then be regarded as a complex 
phenomenon of structural organization that is governed by the nature of constituent 
hydrophilic and hydrophobic blocks, their relative lengths, as well as properties of the 
solvent-phobic block that is the driving force for self-assembly. The inherent 
biocompatibility and biodegradability of polypeptides is of additional advantage for their 
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biological applications. For the purpose of the current study, amphiphilic block copolymer 
with following composition was chosen: polyethylene glycol (PEG) as the hydrophilic, 
stealth imparting block and polyleucine (PLeu) as the hydrophobic part and the initiator of 
micelle formation in aqueous environment. The variables explored in the current study 
were altering the ratio of lengths of constituent blocks as well as chirality of PLeu block 
and the temperature of solvent used for preparation of micelles via the film rehydration 
method. The impact of all these variables on the thermodynamic stability as well as type 
of secondary structures formed and the influence of these attributes on the ability of the 
micelles to encapsulate a combination of hydrophobic drugs into their core are also 
described.   
The primary purpose of designing this micellar carrier was for combination therapy of 
ErbB2 positive breast cancer. The receptor tyrosine kinase, ErbB2 is a viable target in 20-
25 % breast cancer patients due to its overexpression. Its degradation is associated with 
slower progression of the disease and increased survival times. While the monoclonal 
antibody Trastuzumab (Herceptin™) is the first line therapy in such patients, monotherapy 
with Trastuzumab has shown little benefit and therefore must be given with 
chemotherapeutic agents. Such combinations also help in delaying the development of 
resistance to Trastuzumab, since multiple cellular pathways can be targeted 
simultaneously. ErbB2 is a client protein of heat shock protein 90 and 17-N-allylamino-17-
demethoxygeldanamycin (17-AAG) is a potent inhibitor of HSP90. Previous work in our 
lab has demonstrated strong synergy of action between 17-AAG and a model cytotoxic 
agent doxorubicin. In order to further improve the efficacy of the therapy, our goal was to 
replace doxorubicin with a more potent, clinically relevant agent paclitaxel (PTX), which 
has been shown to have strong synergistic antitumor effect with 17-AAG in ErbB2-driven 
breast cancers. Since synergy of such therapy is often sequence and dose ratio specific, 
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co-delivery of the drugs via the same vehicle is desirable as well as beneficial. Dual drug-
loaded micelles thus prepared could load 17-AAG and PTX in a ratio 2:1 by weight. The 
formulation showed a high level of synergy on BT-474 cells that express a high amount of 
ErbB2 while the synergy was negligible in ErbB2low MCF-7 cells. The strong synergy also 
observed when the formulation was tested in an orthotopic breast cancer mouse model 
developed using ErbB2 overexpressing BT-474 cells, and an arrest in the growth of tumors 
in animals treated with dual drug-loaded micelles was observed, while both 17-AAG and 
PTX were used at sub therapeutic doses of 10 mg and 5 mg equivalents per kg body 
weight. The lower doses also helped avoid toxicity associated with the therapy. We also 
show the importance of simultaneously delivering the two drugs via a single carrier system 
as opposed to cocktail of individual drug-loaded micelles administered at equivalent 
doses, which has a better therapeutic outcome than the cocktail therapy. These 
combination drug-loaded micelles were developed as a platform for chemotherapy with 
Trast. The triple therapeutic system of Trast with combination drug-loaded micelles 
containing 17-AAG and PTX exhibited an even stronger anticancer effect, with complete 
regression of tumors at the end of treatment, which reached a palpable size again after 
day 45 with much slower progression than other treatment controls.  
Chapter 2 was thus focused on the development of antibody conjugates to improve the 
therapy of ErbB2 positive breast cancer. The goals were to take advantage of synergy of 
action with multiple therapeutically active components and at the same time explore the 
scope of dose reduction to avoid the eventuality of increased combined toxicity of the 
multiple therapeutic agents used.  The present study demonstrates the importance of 
biophysical characteristics of core-forming polyleucine block for the preparation of stable 
micelles that can load hydrophobic drugs. The self-assembly behavior of the block 
copolymer PEG-PLeu was dictated not only by the lengths of both constitutive blocks but 
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also the conditions of preparing these micelles. Thin film rehydration at elevated 
temperature of 60 ⁰C lead to the formation of relatively small sized micelles with a low 
polydispersity index. The nature of polyleucine block was also an important parameter for 
consideration; racemic poly(D,L)-Leu block had a smaller hydrodynamic diameter and 
much higher capacity for encapsulation of hydrophobic drugs as compared to the 
enantiomeric ally pure poly(L)-Leu block. PEG-P(D,L)-Leu micelles were able to 
encapsulate both 17-AAG and PTX in a weight ratio of 2:1. This ratio showed a high level 
of synergy of cytotoxic action on ErbB2 overexpressing breast cancer cell line BT-474. 
When tested in an in vivo orthotopic mouse model of breast cancer, combination delivery 
via the same carrier had superior anticancer effect as compared to cocktail of individual 
drug-loaded micelles administered at the same drug ratio. Most importantly, marked 
antitumor effect was seen at a sub therapeutic doses of both 17-AAG and PTX, which lead 
to much better tolerability of the therapy and lack of signs of acute toxicity. This 
combination drug-loaded micellar carrier when conjugated with Trast showed complete 
retardation of tumor growth for prolonged period of time, without any signs of acute toxicity, 
which translated into the longest survival time amongst all treatment groups.      
Chapter 3 was focused on development of combinatorial therapy for the treatment of 
pancreatic cancer. The goals of this part were to develop synergy-dependent sequential 
drug therapy that could be administered as a single dose. Pancreatic cancer (PC) is one 
of the most lethal malignancies, due to aggressive tumorigenicity, early metastasis and 
development of drug resistance to standard care chemotherapy. Since its approval in 
1997, Gemcitabine (Gem) has been the first-line treatment for advanced disease. 
However, there is no standard second-line therapy after Gem failure. FOLFIRINOX, a 
combination of four agents, folinic acid, fluorouracil, irinotecan and oxaliplatin was 
approved by the FDA in 2010. The rationale for this combination was based on these 
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drugs having a different mechanism of action, and, more importantly, non-overlapping 
toxicities. In cases that could tolerate FOLFIRINOX, an overall improvement in the survival 
times as well as quality of life was noted. However, even the toxicities are non-overlapping, 
the cumulative toxicity profile for FOLFIRINOX can become the dose limiting factor. In the 
first trial itself, 50.8% of the patients needed dose adjustment. The common toxicities 
observed with FOLFIRINOX include Febrile neutropenia, Thrombocytopenic 
bleeding, ≥ grade 3 platelets, Grade 2 persistent neurotoxicity, Grade 3 persistent 
neurotoxicity  OR Grade 4 neurotoxicity and many more non-hematological toxicities. Most 
of the toxicities are severe enough to require discontinuation of the treatment or switching 
to lower doses or alternative agents. The combination of Gem with Cisplatin (CDDP) has 
been explored in clinical trials for metastatic disease. As a part of FOLFIRINOX, platinum 
compounds showed significant efficacy. Cisplatin acts by damaging the DNA. It is known 
to first get converted into the aqua form within the cell, which happens by the replacement 
of the labile chloro groups with water molecules. This active form is then able to form 
covalently linked adducts with the DNA. This initial assault then goes on to activate a 
series of signaling pathways that ultimately lead to apoptosis and cell death. The DNA 
adducts thus formed can cause distortion of the DNA and subsequent recognition by 
various cellular proteins. This leads to problems in DNA synthesis and replication and is 
reported to cause a prolonged G2 cell-cycle phase arrest. However, the exact mechanism 
of activation of the apoptotic pathways remains unclear. On the other hand, gemcitabine 
is a deoxycytidine analog. Its mechanism of activation involves conversion into its 
triphosphate form, which can then be incorporated into the DNA as a false nucleotide. 
Usually, one more deoxynucleotide can be incorporated into the DNA before the synthesis 
stops. Another minor mechanism of action of gemcitabine is its ability to inhibit 
ribonucleotide reductase, which plays a key role in the repair mechanism of the DNA. 
Many studies report the benefit of administration of gemcitabine prior to that of cisplatin; 
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the reason cited for this is the increase in the formation of Pt-DNA adducts when the DNA 
had already been damaged and exposed due to the incorporation of deoxycytidine or 
active gemcitabine. The gemcitabine in turn inhibits the repair of the formed Pt-DNA 
adducts as well as reduces the efficacy of nucleotide excision repair by its ability to inhibit 
the action of ribonucleotide reductase. On the other hand, when Pt compounds are 
administered prior to gemcitabine, the formed Pt-DNA adducts can no longer allow for the 
incorporation of gemcitabine and that leaves no scope for gemcitabine to act. Our 
preliminary in vitro studies with the free drugs on T3M4 Simple Cells (COSMC deleted 
cells) showed that synergy of the combination is schedule-dependent, and Gem 
administration followed by CDDP showed the most potent cytotoxic activity. However, this 
combination proved to be only marginally effective in actual practice due to combined 
increased toxicity of both the agents. We have shown that encapsulation of CDDP in 
polymeric nanogels with cross-linked ionic cores enhanced its tumor accumulation and 
improved its safety profile. Additionally, sustained release profile of CDDP from nanogels 
allows for the administration of free Gem and CDDP loaded nanogels in a single injection 
while still retaining schedule-dependent synergy of the combination. Pancreatic ductal 
adenocarcinoma cells are known to express truncated O-glycans (Tn and STn antigens) 
and it was shown that decorating the nanogels with an antibody directed against this 
antigen further enhanced their uptake by tumor cells while reducing off-target 
accumulation in an in vivo pancreatic cancer model. Thus, in this study, we demonstrated 
that TKH-2 decorated nanogels were effective in delivering higher payloads of nanogels 
encapsulating CDDP. This lead to a better therapeutic efficacy in terms of tumor growth 
retardation as well as avoidance of acute toxicity, when tested in an orthotopic pancreatic 
cancer murine model. The sequential administration of Gem followed by CDDP that had 
the highest synergy was also maintained in vivo for enhanced therapeutic efficacy. Most 
importantly, this formulation approach allowed for the administration of both the drugs in 
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the same dose and still achieved sequential administration. At the same time, 
encapsulation of CDDP into tumor-targeted NGs allowed to mitigate the toxicity associated 
with the combination of Gem and CDDP.   
LIMITATIONS AND FUTURE DIRECTIONS 
The data reported in chapter 2 showed preclinical evaluation of PTX, 17-AAG and Trast 
in the form of antibody-nanoparticle conjugates. The nanoparticles were micelles made 
from a biodegradable polymer and showed great therapeutic efficacy at sub-therapeutic 
doses of both 17-AAG and PTX. This is work demonstrates the advantages of 
encapsulation of small molecule drugs into nanocarriers, that alters their pharmacokinetics 
favorably, enabling the system to achieve therapeutic efficacy at sub therapeutic doses.  
While in the first part of this chapter only the dual drug-loaded nanocarrier was evaluated, 
the second part consisted of testing the system’s efficacy upon conjugation with Trast. 
Trast acted as a therapeutic as well as targeting ligand, further improving the anticancer 
response obtained with combination of 17-AAG and PTX. While such actively targeted 
systems can overcome the drawbacks of relying solely on the EPR effect due to 
heterogeneity in the tumor vasculature, there is still some variability in responses 
observed. A major limitation of the diblock copolymer PEG-PLeu is that it can load 17-
AAG and PTX in one specific dose ratio only; while that ratio is highly synergistic, the best 
case scenario would be to have a carrier system that allows for varying the ratio of the two 
drugs and screen those ratios for efficacy. There is always scope to play with the 
hydrophobic block to improve the loading capacity for the hydrophobic drugs and achieve 
smaller sizes of the micellar carriers. The research in our lab is currently focused on the 
development of novel block copolymers with better loading capacities for hydrophobic 
drugs as well as being able to manipulate the ratio in which two drugs can be encapsulated 
into the same carrier. The ErbB2 receptor is known to have impaired endocytosis, which 
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is known to be improved by inhibition of HSP90 by 17-AAG. The impaired endocytosis 
also happens to be one of the primary reasons for resistance to Trast that some ErbB2 
positive tumors exhibit. While our system shows very good efficacy on Trast-sensitive cell 
lines, our future work involves testing the efficacy of the system on Trast-resistant cell 
lines and due modifications therein to achieve better therapeutic response, in terms of the 
choice of drugs as well as dose ratios. However, this is a model system that can be used 
as a platform across many cancer types for the development of antibody-nanoparticle 
conjugates. Additionally, testing of the system in a transgenic mouse model instead of an 
orthotopic xenograft should provide a better understanding of the working potential of our 
system.  
 The current therapy for pancreatic ductal adenocarcinoma remains surgical 
resection or debulking of the tumor mass followed by chemotherapy and/or radiotherapy. 
Gemcitabine remains the first line therapy and resistant or relapsed cases are treated with 
FOLFIRINOX. However, FOLFIRINOX, which is a cocktail of 4 different agents, has 
severe dose-limiting toxicity and thus our efforts were to develop a combination regimen 
using Gemcitabine and a platinum drug. We chose cisplatin as our model agent for the 
proof of concept study. However, the current clinical platinum agent used is oxaliplatin, so 
our future study will involve using oxaliplatin in combination with gemcitabine. The PEG-
b-PMA nanogels used are biocompatible, so our future efforts are directed towards the 
development of biodegradable carriers. Many recent studies have shown that the 
particulate system with the size less than 50 nm has profound effect on its tumor 
accumulation. Although we were able to generate particles with the size less than 100 nm, 
it wasn’t small enough for the very effective tumor accumulation as per recent reports. 
This is especially true for poorly vascularized cancers like the pancreatic cancer, and may 
further improve the therapeutic outcome. The targeting antibody, TKH-2 can also be 
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replaced with a monoclonal antibody that has a therapeutic as well as targeting function. 
The current clinical trend is towards the use of immunostimulatory monoclonal antibodies 
and many of them are in clinical trials. Most often, these mAbs inhibit immunosuppressive 
receptors like that cytotoxic T lymphocyte-associated protein 4 (CTLA4) or programmed 
cell death receptor 1 (PD1) and so on, that ultimately results in the activation of T 
lymphocytes or natural killer cells. CTLA4-blocking mAbs, viz., ipilimumab and 
tremelimumab and PD1 targetign nivolumab are being tested in clinical trials and have 
shown promising results. One such antibody would be ab ideal candidate to design 
antibody-nanoparticle conjugates with gemcitabine and oxaliplatin for the therapy of 
pancreatic cancer.    
